{
  "1374140386071961602": {
    "tweet_author": "Hematopoiesis News",
    "tweet_text": "\u2695\ufe0f Scientists conducted a Phase II study of acalabrutinib in patients with relapsed/refractory #CLL who were ibrutinib-intolerant, and found an overall response rate of 73%. \nhttps://t.co/eJ6m4QpC5P https://t.co/kuZz6ZO47r"
  },
  "1374032432173842437": {
    "tweet_author": "Michael Wang, MD",
    "tweet_text": "This phase 2 Acalabrutinib-Venetoclax (AV) trial that is still in recruitment phase will study how well venetoclax and acalabrutinib works in MCL patients who either relapsed or non-respondent to the initial therapy.\n\nhttps://t.co/gg0G9At23N"
  },
  "1373902876553048065": {
    "tweet_author": "1stOncology",
    "tweet_text": "#NICE backs #AstraZenecas #Calquence for #CLL https://t.co/Vb5lPDoGrA"
  },
  "1373656782367813635": {
    "tweet_author": "Toby Eyre",
    "tweet_text": "#acalabrutinib is a valuable option in pts intolerant to #ibrutinib. Further valuable data to help decision making in #CLL \n\nEarly View | Haematologica https://t.co/Z2kCLZaX0D"
  },
  "1372941634334232586": {
    "tweet_author": "Lymphoma Hub",
    "tweet_text": "NICE has recommended the use of acalabrutinib for patients with treatment-na\u00efve chronic lymphocytic leukemia. Find out more here https://t.co/6OuJptLCIN #lymsm #lymphoma"
  },
  "1372927482278539265": {
    "tweet_author": "David Ledger",
    "tweet_text": "NICE backs AstraZeneca\u2019s Calquence for CLL https://t.co/JOPNLNID5R https://t.co/9pwY4NKP4s"
  },
  "1372911723305394179": {
    "tweet_author": "N Wales Cancer Forum",
    "tweet_text": "This is England for now - these decisions usually come to Wales too. \nMore info\n\n https://t.co/SR5TU0ZSHH https://t.co/OFdwEdlav6"
  },
  "1372888121159868423": {
    "tweet_author": "European Pharmaceutical Review",
    "tweet_text": "AstraZeneca\u2019s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to patients with chronic lymphocytic #leukaemia.\n#oncology #drugapprovals #pharma #healthnews\nFind out more here: https://t.co/qYUft2Cn8b https://t.co/Sxve6NGGX3"
  },
  "1372866915081797632": {
    "tweet_author": "Graham Collins",
    "tweet_text": "Superstar @tobyeyre82 responding to the excellent news of NICE approval of acalabrutinib in frontline CLL for FCR / BR unsuitable patients. https://t.co/lACvpOtrWx"
  },
  "1372825553837944834": {
    "tweet_author": "CLL Ireland",
    "tweet_text": "CLL patients all know the drug Ibrutinib and yesterday in the UK Acalabrutinib was approved and now a new drug Pirtobrutinib is making a big impact for relapsed patients in recent #clinicaltrials\n@cancertrials_ie @CllSociety @LAL_NI @BloodCancerIRL\nhttps://t.co/murr3KPhsZ"
  },
  "1372788676191608837": {
    "tweet_author": "Mice Ideas",
    "tweet_text": "Optimal Management of High-Risk CLL with Acalabrutinib\n19 March 2021 | 7.00 pm - 8.30 pm\n\nSpeaker 1 - Dr P G Subramanian, Mumbai \nSpeaker 2 - Group Captain (Dr) Harshit Khurana, Pune\n\nChair: Dr S H Advani, Mumbai\nModerator: Dr M B Agarwal, Mumbai\n\nLink: https://t.co/ou2dEMfIcE https://t.co/nvAeDoMRll"
  },
  "1372662881230188555": {
    "tweet_author": "Farooq A Wandroo",
    "tweet_text": "Acalabrutinib for all forms of CLL, NICE today.get ready  @SwbhPharmacy @StevenShanu @HojanSenya\n@SWBH_RandD @Oncology_at_AZ https://t.co/pG1GaUtZ5j"
  },
  "1372583112723533827": {
    "tweet_author": "Leukaemia Care",
    "tweet_text": "It has been announced today (Thursday 18th March) that The National Institute for Health and Care Excellence (NICE) have made recommendations for acalabrutinib to become a treatment option for certain groups of chronic lymphocytic leukaemia (CLL) patients in England."
  },
  "1372558560543047693": {
    "tweet_author": "Helen Oram",
    "tweet_text": "NICE has recommended the use of acalabrutinib, as a monotherapy option for adults with:\n\u2022a 17p\u00a0deletion or TP53\u00a0mutation, or\n\u2022no 17p\u00a0deletion or TP53\u00a0mutation, and fludarabine plus cyclophosphamide and rituximab (FCR), or bendamustine plus rituximab (BR) is unsuitable. https://t.co/ntYG8VLKyZ"
  },
  "1372549029767299076": {
    "tweet_author": "HealthWatch",
    "tweet_text": "A brand new oral treatment, Acalabrutinib, taken as a twice daily tablet, for untreated  blood cancer, chronic lymphocytic leukaemia, has today (Thursday 18 March 2021) been recommended for NHS use by NICE.\nhttps://t.co/nLoyYbepRA"
  },
  "1372529109805510658": {
    "tweet_author": "PHARMABOX.IN",
    "tweet_text": "NICE backs AstraZeneca\u2019s Calquence for CLL https://t.co/P6fy1o0mTi"
  },
  "1372528985691746305": {
    "tweet_author": "Pharma Trader",
    "tweet_text": "NICE backs AstraZeneca\u2019s Calquence for CLL https://t.co/V0wjoKqqTm"
  },
  "1372528101335265284": {
    "tweet_author": "Everything Pharma",
    "tweet_text": "NICE backs AstraZeneca\u2019s Calquence for CLL https://t.co/8RAQ6sLJIs"
  },
  "1372526440680333314": {
    "tweet_author": "IJPSonline",
    "tweet_text": "NICE backs AstraZeneca\u2019s Calquence for CLL https://t.co/hKPfa0IW6N"
  },
  "1372519291635998731": {
    "tweet_author": "Iceberg Vision",
    "tweet_text": "NICE backs AstraZeneca\u2019s Calquence for CLL https://t.co/6b1RYaHRxX"
  },
  "1372515771205742604": {
    "tweet_author": "PharmaTimes",
    "tweet_text": "NICE backs AstraZeneca\u2019s Calquence for CLL https://t.co/FTEaEMFSW7 #pharma #lifesciences"
  },
  "1372510731795492867": {
    "tweet_author": "Paperbirds_Hematology",
    "tweet_text": "New article: Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia https://t.co/osJpzYCezE #CLL #leusm #hematology"
  },
  "1372490442911141897": {
    "tweet_author": "Pharma News",
    "tweet_text": "TARGETED ORAL MONOTHERAPY CALQUENCE (ACALABRUTINIB) RECOMMENDED BY NICE FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)\nhttps://t.co/tJ2w5zcKD3\n#PharmaNews #ClinicalResearchNews #BiotechNews #LifeSciencesNews #MedicalNews #HealthcareNews #PharmiwebNews https://t.co/wYA5UUOJqo"
  },
  "1372475756845137920": {
    "tweet_author": "CLL Ireland",
    "tweet_text": "As the UK approve new treatments for #CLL with Acalabrutinib now available. Ireland falls far behind.\nPatients need better options. \n@JanRynne @DonnellyStephen @HSELive @davidcullinane @hseNCCP @paulreiddublin @IPPOSI @PaulMcauliffe @RoisinShortall https://t.co/tW2zAInOlp"
  },
  "1372473228938084360": {
    "tweet_author": "pharmaphorum",
    "tweet_text": ".@NICEComms backs NHS use for @AstraZeneca\u2019s Calquence for new leukaemia indication, and @DaiichiSankyo\u2019s cholesterol-lowering drugs Nilemdo and Nustendi #heor https://t.co/PqFk7N9pCi"
  },
  "1372473109287215104": {
    "tweet_author": "Toby Eyre",
    "tweet_text": "#Acalabrutinib @NICEComms approved for 1L #CLL in UK\n- All pts considered unfit for FCR or BR\n- All pts TP53 mut/del\n- All relapsed CLL\n\nEnjoyed talking about this with @CLLSupport Chair of Trustees Marc Auckland on Sky News this am. \n\nGreat news for our #CLL pts! @bloodcancer_uk https://t.co/Sh0iIDgKel"
  },
  "1372447809467777025": {
    "tweet_author": "Lymphoma Papers",
    "tweet_text": "Safety and Antitumor Activity of Acalabrutinib for Relapsed/Refractory B-cell Malignancies: A Japanese Phase I Study #lymphoma #lymsm https://t.co/NrxD4YK0zm"
  },
  "1372240588527968259": {
    "tweet_author": "Paperbirds_Hematology",
    "tweet_text": "New article: Safety and Antitumor Activity of Acalabrutinib for Relapsed/Refractory B-cell Malignancies: A Japanese Phase I Study https://t.co/iVdJs3l0Z0 #CLL #leusm #hematology"
  },
  "1371884004950089733": {
    "tweet_author": "Lymphoma Hub",
    "tweet_text": "Congress| #EBMT21 | @michaelwangmd, @MDAndersonNews, discussed results of the ZUMA-2 study in R/R mantel cell lymphoma by morphology and prior BTKi exposure to ibrutinib and/or acalabrutinib. He concluded that all subgroups drew clinical benefit from KTE-X19 treatment. #lymsm https://t.co/vufXrfRbgD"
  },
  "1371398643236925441": {
    "tweet_author": "Trip Database",
    "tweet_text": "New2Trip: Acalabrutinib (Calquence) for treatment of chronic lymphocytic leukaemia (CLL) https://t.co/mR2qsZwCZX"
  },
  "1370026180603117580": {
    "tweet_author": "Osgood",
    "tweet_text": "Calquence Commercial Had A REALLY PRETTY Lady In it @CHANEL @TwitterSupport A nurse I think"
  },
  "1367801199638896640": {
    "tweet_author": "Paperbirds_Hematology",
    "tweet_text": "New clinical trial: Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma https://t.co/I42benJlRg #MCL #lymsm #hematology"
  },
  "1367440609896710145": {
    "tweet_author": "Thiago Carvalho",
    "tweet_text": "'Solidarity negotiated with Astra-Zeneca to test its cancer drug acalabrutinib, which dampens the immune system. Investigators changed treatment protocols to include the medicine, but then the company decided not to give the green light.'\n\nhttps://t.co/x65mJlnv42"
  },
  "1366770231289536522": {
    "tweet_author": "Kartos Therapeutics",
    "tweet_text": "ICYMI, please view our #ASH20 TiP poster presentation about a new study that will explore the combination of KRT-232 (MDM2i) + acalabrutinib in patients with R/R B-Cell malignancies. https://t.co/g5uOottDLo. Find out more at https://t.co/sgbNXj8zNx #LYMSM #CLL #DLBCL"
  },
  "1365755830574977026": {
    "tweet_author": "Apoli Naria",
    "tweet_text": "IQVIA RDS Argentina S.R.L. representa en Argentina a \n1. Janssen Vaccines &amp; Prevention B.V.\n2. Pharma B.V.\n3. AstraZeneca AB\n4. Amgen Inc.\n\nACALABRUTINIB\nApremilast\nLanadelumab\nAbatacept-remdesivir-infliximab-mesilato de cenicriviroc\n\nhttps://t.co/KuRUk5RKIY\n\ncc:  @spitta1969"
  },
  "1365449441398915076": {
    "tweet_author": "Michael Wang, MD",
    "tweet_text": "Maria, we appreciate you!\nOur group has passed 4 FDA inspections. In 2013, we led Ibrutinib FDA approval; in 2017, we led acalabrutinib FDA approval and in 2020, we led Brexucarbatagene Autoleucel FDA approval. Without your leadership and our wonderful team, not possible! https://t.co/FPUMj4qaq2"
  },
  "1364491860954259459": {
    "tweet_author": "Cardio-Targets",
    "tweet_text": "The role of acalabrutinib in adults with chronic lymphocytic leukemia https://t.co/xv81it4zeO"
  },
  "1364304315838582793": {
    "tweet_author": "Lymphoma Papers",
    "tweet_text": "The role of acalabrutinib in adults with chronic lymphocytic leukemia #lymphoma #lymsm https://t.co/LVp7uro7so"
  },
  "1364302784938475521": {
    "tweet_author": "Paperbirds_Hematology",
    "tweet_text": "New article: The role of acalabrutinib in adults with chronic lymphocytic leukemia https://t.co/XRlUn5eVpU #CLL #leusm #hematology"
  },
  "1364189928133976069": {
    "tweet_author": "Cardio-Targets",
    "tweet_text": "The role of acalabrutinib in adults with chronic lymphocytic leukemia. https://t.co/aPrU50bG9R"
  },
  "1364169662267682820": {
    "tweet_author": "Paperbirds_Hematology",
    "tweet_text": "New article: The role of acalabrutinib in adults with chronic lymphocytic leukemia. https://t.co/YAnuxMbr89 #CLL #leusm #hematology"
  },
  "1364019275279654912": {
    "tweet_author": "Jeff Sharman",
    "tweet_text": "The role of CD20 in addition to BTK inhibitors is not a closed story.  We previously published obinutuzumab benefit with acalabrutinib (https://t.co/klsjuwWfDM).  \n\nNow we show, Ublituximab to Ibrutinib has benefit in 17P #TGTherapeutics @anthonymatomd \n\nhttps://t.co/l7qRcv0uDS"
  },
  "1363455819493310464": {
    "tweet_author": "Paperbirds_Hematology",
    "tweet_text": "New clinical trial: Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma https://t.co/KpdyK3KvOO #MCL #lymsm #hematology"
  },
  "1362729902856941568": {
    "tweet_author": "IM M\u00e9dico",
    "tweet_text": "Acalabrutinib alcanza el objetivo primario de eficacia en comparaci\u00f3n con ibrutinib en LLC @AstraZenecaES       \n https://t.co/4VTn1Bsx5O"
  },
  "1362727073329131520": {
    "tweet_author": "FirstWord Pharma",
    "tweet_text": "Physician Views Preview: Digging into the impressive US launch of AstraZeneca's Calquence $AZN https://t.co/MV4LVMUuQb"
  },
  "1361822683227389957": {
    "tweet_author": "CancerNetwork\u00ae, Home of the Journal ONCOLOGY\u00ae",
    "tweet_text": "#ICYMI: Overall, the phase 3 ELEVATE-RR trial demonstrated efficacy of acalabrutinib and a safety and tolerability profile that with was consistent with that observed in the broader acalabrutinib clinical development program.\nhttps://t.co/m89J49LBfC"
  },
  "1360604941971316737": {
    "tweet_author": "Tom Henry, MBA, RPh, CPh",
    "tweet_text": "CLL Research: Acalabrutinib \u2013 An Analysis of Cardiovascular\u00a0Events https://t.co/sPoUZ0fDnp"
  },
  "1360504470883475456": {
    "tweet_author": "Medivizor",
    "tweet_text": "Comparing acalabrutinib to standard treatments in patients with chronic lymphocytic l... https://t.co/tLXIunsT1a via @medivizor #Leukemia"
  },
  "1360378272148815874": {
    "tweet_author": "mednetnews",
    "tweet_text": "MCL Survival Likely Affected by Reason for Acalabrutinib\u00a0Discontinuation https://t.co/HSJCzH0Kq2"
  },
  "1360319765252886533": {
    "tweet_author": "AJMC",
    "tweet_text": "Mantle Cell Lymphoma Survival Likely Affected by Reason for Acalabrutinib Discontinuation: https://t.co/CBfJM8GhPy https://t.co/plFzmtrPzO"
  },
  "1359883921979244551": {
    "tweet_author": "Patient Worthy",
    "tweet_text": "CALQUENCE Beneficial for CLL, Study Shows https://t.co/zlYXexHKa7 #calquence #CLL #chroniclymphocyticleukemia #rarecancer #treatment @LLSusa"
  },
  "1359503020694798338": {
    "tweet_author": "Paperbirds_Hematology",
    "tweet_text": "New clinical trial: ALICIA (Acalabrutinib in CLL Therapy) https://t.co/xuHPwIu5mO #CLL #leusm #hematology"
  },
  "1358937124423290884": {
    "tweet_author": "Cat",
    "tweet_text": "https://t.co/NDVz7aYo0K"
  },
  "1358840804928876545": {
    "tweet_author": "Hemalatha Rangarajan MD",
    "tweet_text": "#TCTM21 #gvhdsm #chronicGVHD @StephanieLeeMD Number of registered studies for cGVHD, drugs in these studies, a newer \"itinib\" : oral acalabrutinib https://t.co/CXLx3uWEcv"
  },
  "1358182533498871808": {
    "tweet_author": "mednetnews",
    "tweet_text": "Mantle Cell Lymphoma Treatment Market By Product Type (Acalabrutinib, JCAR-017) And By End-Users/Application (Hospital, Clinic) Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2021 \u2013\u00a02028 https://t.co/h3S3OG3G7n"
  },
  "1358089001689702401": {
    "tweet_author": "Bita Fakhri",
    "tweet_text": "In this review, we tried to situate #acalabrutinib among the treatment options for patients with treatment-naive and rel/ref CLL.  https://t.co/ajnFfceVEp"
  },
  "1357362376916545538": {
    "tweet_author": "NCPE",
    "tweet_text": "Acalabrutinib (Calquence\u00ae) | HTA ID: 20063 | National Centre for Pharmacoeconomics | https://t.co/hVpLP5zE5b https://t.co/wi0DvbZXZt"
  },
  "1357356433310965761": {
    "tweet_author": "JOURNAL ONKOLOGIE",
    "tweet_text": "News von https://t.co/y3RvLBtHWZ \u2013 Lesen Sie jetzt den vollst\u00e4ndigen Beitrag unter:\nhttps://t.co/C0MrJSBxlu\n\n#Arzt #Schmerz #CLL_Immunchemotherapie #Leuk\u00e4mie #Immuntherapie #Neutropenie #Mutation #Acalabrutinib #Patient #Therapie #Unvertr\u00e4glichkeiten #Zulassung #Studie"
  },
  "1357056544454676489": {
    "tweet_author": "Oncology Learning Network",
    "tweet_text": "In this video, Dr Danilov, @OHSUNews, discusses the use of #acalabrutinib, (@CalquenceHCP) as a treatment option for #patients with CLL, SLL, and MCL.\n\nWatch Here: https://t.co/UULj3g798S\n\n#MedEd #MedTwitter #Healthcare https://t.co/0FHgk0h1V1"
  },
  "1356950776388739073": {
    "tweet_author": "Oncology Learning Network",
    "tweet_text": "In this video interview, Dr Graff, @MercyOneDSM, discusses the evolving treatment landscape for #CLL in recent years, especially with the introduction of #acalabrutinib (Calquence; AstraZeneca).\n\nWatch Here: https://t.co/tDq0yoIVV7 https://t.co/0zw9GEAp1W"
  },
  "1356497620923998214": {
    "tweet_author": "OncLive.com",
    "tweet_text": "For the phase 3 trial, investigators set out to evaluate PFS benefit with acalabrutinib versus ibrutinib in previously treated patients with high-risk CLL. #leusm https://t.co/RFP5ZFI9Ua"
  },
  "1355979506071330819": {
    "tweet_author": "Medivizor",
    "tweet_text": "Comparing acalabrutinib to standard treatments in patients with chronic lymphocytic... from @medivizor: https://t.co/tLXIunsT1a #Leukemia"
  },
  "1355636954474426374": {
    "tweet_author": "TrialSite News",
    "tweet_text": "AstraZeneca\u2019s Calquence Meets Primary Efficacy Endpoint in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia\n\nhttps://t.co/k6GGKO69lZ\n\n#Hematology #Oncology #Acalabrutinib #CLL #PFS #n=533 #AstraZeneca https://t.co/RM308oXVa3"
  },
  "1355553403645136897": {
    "tweet_author": "Trip Database",
    "tweet_text": "New2Trip: Acalabrutinib https://t.co/Xn7yfvxE1z"
  },
  "1355155741980708864": {
    "tweet_author": "Lyfebulb",
    "tweet_text": "Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia https://t.co/QC1WDwWCcp #chronicillness #digitalhealth #Lyfebulb"
  },
  "1355017852793856003": {
    "tweet_author": "OncLive.com",
    "tweet_text": "Acalabrutinib showed noninferior progression-free survival and a significantly lower incidence of atrial fibrillation versus ibrutinib in patients with high-risk chronic lymphocytic leukemia. #leusm https://t.co/oYihNdET4I"
  },
  "1354878082621071361": {
    "tweet_author": "The Medical Ed Cons.",
    "tweet_text": "AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica \n\nhttps://t.co/hg4z5BVkTK"
  },
  "1354841708723392519": {
    "tweet_author": "CancerNetwork\u00ae, Home of the Journal ONCOLOGY\u00ae",
    "tweet_text": "Overall, the phase 3 ELEVATE-RR trial demonstrated efficacy of acalabrutinib and a safety and tolerability profile that with was consistent with that observed in the broader acalabrutinib clinical development program. | @AstraZeneca \nhttps://t.co/m89J49LBfC"
  },
  "1354542241210101763": {
    "tweet_author": "CarnivoresHealth",
    "tweet_text": "AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica https://t.co/lvZyqYFRzA https://t.co/Ek3TTOltU4"
  },
  "1354537187526717445": {
    "tweet_author": "Portfolio Penny",
    "tweet_text": "AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica https://t.co/AAQF9Btz5m https://t.co/1oki6GxPjP"
  },
  "1354537173362597892": {
    "tweet_author": "FancyFinancy",
    "tweet_text": "AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica https://t.co/h9uHkFDvpk https://t.co/YSaNwCZglK"
  },
  "1354534707250290689": {
    "tweet_author": "Robo Schmobo",
    "tweet_text": "AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica https://t.co/bfn5cRAVG0 https://t.co/qC3sL5xBce"
  },
  "1354532137559617536": {
    "tweet_author": "Financial Carnivores",
    "tweet_text": "AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica https://t.co/Showno9jIh https://t.co/Fxx7gKb1Ww"
  },
  "1354474488709181441": {
    "tweet_author": "Lymphoma Hub",
    "tweet_text": "News| Acalabrutinib has met the primary endpoint of non-inferior PFS vs ibrutinib in the phase III ELEVATE-RR trial for R/R CLL. Find out more here https://t.co/QarwKGmNJE #lymsm https://t.co/PIpTt2tbG3"
  },
  "1354423095872917504": {
    "tweet_author": "NetCancer",
    "tweet_text": "[#AMMH\u00e9mato]\nL'acalabrutinib un nouveau traitement chez les patients adultes atteints d\u2019une #Leuc\u00e9mie Lympho\u00efde Chronique. \nRetrouvez tous les d\u00e9tails de cette mol\u00e9cule sur notre Findrugs \ud83d\udcbb https://t.co/tvRzX0NLcp\n\n#cancer #innovation #informationpatient #h\u00e9matologie #traitement https://t.co/MLpo9wMwbk"
  },
  "1354238697466687495": {
    "tweet_author": "DMGAZ",
    "tweet_text": "A head-to-head study of two #leukemia drugs showed one may be safer relative to side effects associated with cardiac issues. #cardiology #cancer #stroke\nhttps://t.co/zqsVEGSAyV"
  },
  "1354236123413934084": {
    "tweet_author": "Amit Patel\ud83c\uddec\ud83c\udde7",
    "tweet_text": "Impact of #CART therapy in those patients with #mantle cell #lymphoma that remain alive in this cohort after #acalabrutinib failure https://t.co/ceS7lsuoiO"
  },
  "1354231408223514624": {
    "tweet_author": "Blood Advances",
    "tweet_text": "Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib https://t.co/rMiCwSMc1z #CLL https://t.co/vAArexGTfH"
  },
  "1354155126689308673": {
    "tweet_author": "The Medical Ed Cons.",
    "tweet_text": "AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica \n\nhttps://t.co/hg4z5BVkTK"
  },
  "1354135353028997121": {
    "tweet_author": "Silas Inman",
    "tweet_text": "Acalabrutinib Shows Noninferior PFS, Less Atrial Fibrillation Versus Ibrutinib in High-Risk CLL https://t.co/HKnmF6nr5m"
  },
  "1354120316348465160": {
    "tweet_author": "OncLive.com",
    "tweet_text": "Acalabrutinib Shows Noninferior PFS Versus Ibrutinib in High-Risk CLL #leusm https://t.co/ikwuezSI3i"
  },
  "1354082212010979330": {
    "tweet_author": "Targeted Oncology",
    "tweet_text": "In adults with previously treated, high-risk chronic lymphocytic leukemia, treatment with acalabrutinib was found to be non-inferior to treatment with ibrutinib in terms of progression-free survival. #leusm\nhttps://t.co/zaH6KhPFKV"
  },
  "1354081826583830530": {
    "tweet_author": "AnalySource: Premier Drug Pricing Services",
    "tweet_text": "Five things for pharma marketers to know: Tuesday, January 26, 2021 - Roundup - MM&amp;M - Medical Marketing and Media https://t.co/dpi8rn2plu\n\n#COVID19 @BoosterShot #Calquence\n\n@Merck @statnews @MMMnews @nytimes @endpts @politico @CNBC @moderna_tx @AstraZenecaUS @pfizer https://t.co/PVcoPrgYC9"
  },
  "1354072853101084675": {
    "tweet_author": "Helix BioPharma",
    "tweet_text": "AstraZeneca said its Calquence had lower rate of atrial fibrillation cases compared with Johnson &amp; Johnson and AbbVie's rival BTK inhibitor Imbruvica in a head-to-head phase 3 chronic lymphocytic leukemia trial! $AZN $JNJ $ABBV #leukemia #pharma \nhttps://t.co/2n8KV2Mhza"
  },
  "1354067820049539074": {
    "tweet_author": "AlphaBronze",
    "tweet_text": "AstraZeneca said its Calquence had lower rate of atrial fibrillation cases compared with Johnson &amp; Johnson and AbbVie's rival BTK inhibitor Imbruvica in a head-to-head phase 3 chronic lymphocytic leukemia trial! $AZN $JNJ $ABBV #leukemia #pharma \nhttps://t.co/pbHwvaRtai"
  },
  "1354066764825559042": {
    "tweet_author": "TrialSite News",
    "tweet_text": "CALQUENCE met Primary Efficacy Endpoint in head-to-head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia\n\nhttps://t.co/IVzQpTqGyJ\n\n#AstraZeneca #Calquence #Lymphoma #Mantle #Cell #Lymphoma #PFS #CLL #acalabrutinib https://t.co/HSRYADWja1"
  },
  "1354047704561758208": {
    "tweet_author": "Plexus Ventures",
    "tweet_text": "#AZ says #Calquence is a safer drug than #Imbruvica https://t.co/E2rz2ZOOGO via @pharmaphorum #AstraZeneca"
  },
  "1354031181269000192": {
    "tweet_author": "Toby Eyre",
    "tweet_text": "Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib https://t.co/hosYReAEo3"
  },
  "1354021532763185152": {
    "tweet_author": "Paperbirds_Hematology",
    "tweet_text": "New article: The European Medicines Agency Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia. https://t.co/n8i8my1hqy #CLL #leusm #hematology"
  },
  "1354006590479855617": {
    "tweet_author": "BiopharmaAsia",
    "tweet_text": "Calquence approved for the treatment of relapsed or refractory chronic lymphocytic leukaemia in Japan - https://t.co/nmSYYGKfsm"
  },
  "1353989515992395776": {
    "tweet_author": "1stOncology",
    "tweet_text": "#Astrazeneca reported that #CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against #Ibrutinib in #ChronicLymphocyticLeukemia https://t.co/5pJxyiJgxY"
  },
  "1353986275477315585": {
    "tweet_author": "1stOncology",
    "tweet_text": "#Astrazeneca reported that #Calquence approved in Japan for the treatment of  #Relapsed or #Refractory #ChronicLymphocyticLeukaemia https://t.co/ALF5oezQ7J"
  },
  "1353986043012374530": {
    "tweet_author": "Bio_Talent",
    "tweet_text": "Calquence tops Imbruvica in chronic lymphocytic leukaemia study: https://t.co/EcFqJZcqhO\n\nFind us at https://t.co/3dDltqR7h2 https://t.co/5D5dyOckdW"
  },
  "1353985976792608768": {
    "tweet_author": "1stOncology",
    "tweet_text": "#Astrazeneca reported that #Calquence met primary efficacy endpoint in head-to-head trial against #Ibrutinib in #ChronicLymphocyticLeukaemia https://t.co/0hI1lsWQ3e"
  },
  "1353985443113664512": {
    "tweet_author": "Roberto Bonin",
    "tweet_text": "Calquence ha raggiunto l\u2019endpoint primario di efficacia nello studio testa a testa contro ibrutinib nella leucemia linfocitica cronica https://t.co/0xCbBETtfM"
  },
  "1353921460171984896": {
    "tweet_author": "Taro Shiga",
    "tweet_text": "\u30a2\u30b9\u30c8\u30e9\u30bc\u30cd\u30ab\u306e\u30ab\u30eb\u30b1\u30f3\u30b9\u00ae\u3001\u65e5\u672c\u306b\u304a\u3044\u3066\u518d\u767a\uff0f\u96e3\u6cbb\u6027\u6162\u6027\u30ea\u30f3\u30d1\u6027\u767d\u8840\u75c5\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066\u627f\u8a8d\u53d6\u5f97 https://t.co/NbXvW6Yna5 @PRTIMES_JP\u3088\u308a \n\n#acalabrutinib #Calquence\u00ae \n#CLL \n#CardioOnc\n\n\u53d6\u308a\u7d44\u307f\u304c\u3059\u3070\u3089\u3057\u3044\u3067\u3059\u306d\u3063\ud83d\ude00\n\u540d\u524d\u304a\u307c\u3048\u308b\u306e\u5927\u5909\uff0c\u30db\u30f3\u30c8\u306b... https://t.co/pQ8zeoAltz"
  },
  "1353914074472583169": {
    "tweet_author": "Susan",
    "tweet_text": "AstraZeneca touts Calquence safety win against Imbruvica in leukemia trial showdown https://t.co/hdbF9XJQmy"
  },
  "1353885369675223045": {
    "tweet_author": "BioCentury",
    "tweet_text": "Monday's Quick Takes include Comirnaty's provisional approval in Australia and authorization in Hong Kong; plus priority reviews for Albireo and Iterum, and Calquence meets in Phase III CLL trial https://t.co/NvYD2cGqyP"
  },
  "1353877818380152832": {
    "tweet_author": "Endpoints News",
    "tweet_text": "Three years after first launching Calquence as a second generation BTK inhibitor, AstraZeneca continues to tout new data to compete with J&amp;J and AbbVie\u2019s first generation blockbuster Imbruvica. \n\nhttps://t.co/tlGdxMdx3O"
  },
  "1353836952085258241": {
    "tweet_author": "Pharma Top News",
    "tweet_text": "AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica | BioPharma Dive #PharmaTopNews #OncologyTopNews #Oncology  https://t.co/rE3damFX7X"
  },
  "1353836577642962944": {
    "tweet_author": "OncLive.com",
    "tweet_text": "Acalabrutinib Approved in Japan for Relapsed/Refractory CLL #leusm https://t.co/3KLyHko5DQ"
  },
  "1353834280921800705": {
    "tweet_author": "FiercePharma",
    "tweet_text": "AstraZeneca touts Calquence safety win against Imbruvica in leukemia trial showdown https://t.co/kBg8DCFFmB"
  },
  "1353830533491544064": {
    "tweet_author": "Benlazar S.M Amin\u00e9",
    "tweet_text": "Outcomes of relapsed mantle cell #lymphoma patients after discontinuing acalabrutinib - Jain - - American Journal of Hematology - Wiley Online Library\nhttps://t.co/O0qbBGmL3R https://t.co/baT6qqNCKg"
  },
  "1353828627717124097": {
    "tweet_author": "WebWire",
    "tweet_text": "Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia https://t.co/PmCBCUocGS"
  },
  "1353814607492751360": {
    "tweet_author": "Tecnomedicina",
    "tweet_text": "Calquence ha raggiunto l\u2019endpoint primario di efficacia nello studio testa a testa contro ibrutinib nella leucemia linfocitica cronica https://t.co/Bsv3LYniYl"
  },
  "1353798006924046336": {
    "tweet_author": "HemOnc Today",
    "tweet_text": "\ud83c\udd95  Topline results of randomized phase 3 ELEVATE-RR trial show that acalabrutinib exhibits comparable efficacy and superior safety when compared with ibrutinib for chronic lymphocytic leukemia https://t.co/kuiIbqSlOz #CLL @AstraZeneca https://t.co/r26qeEFL8o"
  },
  "1353781577524924416": {
    "tweet_author": "BrainSights iOS App",
    "tweet_text": "CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia - Neuro Central via BrainSights for iOS https://t.co/sQAr3EAIyZ"
  },
  "1353780477354594305": {
    "tweet_author": "Dr Timos Papagatsias",
    "tweet_text": "AstraZeneca touts Calquence safety win against Imbruvica in leukemia trial showdown https://t.co/8kgb7wPFov #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #healthcare #biotech"
  },
  "1353778216037732354": {
    "tweet_author": "NewExpressNews",
    "tweet_text": "AstraZeneca touts Calquence safety win against Imbruvica in leukemia trial\u00a0showdown https://t.co/ShghMeIhrE"
  },
  "1353772372914958336": {
    "tweet_author": "BioPharma Dive",
    "tweet_text": "AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica https://t.co/XobOkLTEUX by @ByJonGardner $AZN $ABBV $JNJ"
  },
  "1353752005303537665": {
    "tweet_author": "Market Intelligence: Healthcare",
    "tweet_text": "AstraZeneca's Calquence was as effective as Johnson &amp; Johnson's Imbruvica in delaying the progression of a type of blood cancer in a late-stage study\nhttps://t.co/m6YkcM0N8A \n$AZN $JNJ https://t.co/lBwf273MRk"
  },
  "1353750800732971010": {
    "tweet_author": "Ben Fidler",
    "tweet_text": "AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica https://t.co/HLhOiJmQzY @ByJonGardner $AZN $ABBV $JNJ $MRK $LLY"
  },
  "1353749995598475264": {
    "tweet_author": "\u524d\u7530\u9759\u543e\uff5c\u6d77\u5916\u60c5\u5831\u6d3b\u7528\u30b3\u30f3\u30b5\u30eb\u30bf\u30f3\u30c8\u3000Insights4 Pharma\u7de8\u96c6\u9577",
    "tweet_text": "AstraZeneca touts Calquence safety win against Imbruvica in leukemia trial showdown https://t.co/rmkHEDOpXj"
  },
  "1353749330667188224": {
    "tweet_author": "PHARMABOX.IN",
    "tweet_text": "AstraZeneca touts Calquence safety win against Imbruvica in leukemia trial showdown https://t.co/aNpVUGEyZS"
  },
  "1353744822947856385": {
    "tweet_author": "cafepharma",
    "tweet_text": "AZ says Calquence is a safer drug than Imbruvica https://t.co/rP5BdqUhoe"
  },
  "1353743444867481601": {
    "tweet_author": "Calgary Herald",
    "tweet_text": "AstraZeneca Says Calquence Approved In Japan For CLL https://t.co/VvdWaQwqay"
  },
  "1353742639498190848": {
    "tweet_author": "Endpoints News",
    "tweet_text": "Three years after first launching Calquence as a second generation BTK inhibitor, AstraZeneca continues to tout new data to compete with J&amp;J and AbbVie\u2019s first generation blockbuster Imbruvica. By: @Jasonmmast\n\nhttps://t.co/tlGdxMv8so"
  },
  "1353736022962573312": {
    "tweet_author": "David Ledger",
    "tweet_text": "Calquence tops Imbruvica in chronic lymphocytic leukaemia study https://t.co/2oWwcmEwbC https://t.co/fZp7ss6Egh"
  },
  "1353733848777936896": {
    "tweet_author": "Biotech & Tech Stock Focus",
    "tweet_text": "$AZN AstraZeneca Reports Positive Phase 3 Results Of Calquence Against Ibrutinib In CLL https://t.co/bc4GDtrXbd"
  },
  "1353729595313332230": {
    "tweet_author": "Dr Timos Papagatsias",
    "tweet_text": "AstraZeneca's Calquence nabs another win against Imbruvica, but Eli Lilly is on its heels https://t.co/CRIH9rtTtV #strategy #competitiveintelligence #marketing #productmarketing #pharma #biotech #pharmaceutical #healthcare https://t.co/FepHag53JZ"
  },
  "1353714838787158016": {
    "tweet_author": "Corporate News",
    "tweet_text": "$AZN CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia https://t.co/y0h0eiMRYD"
  },
  "1353711478658920448": {
    "tweet_author": "\u524d\u7530\u9759\u543e\uff5c\u6d77\u5916\u60c5\u5831\u6d3b\u7528\u30b3\u30f3\u30b5\u30eb\u30bf\u30f3\u30c8\u3000Insights4 Pharma\u7de8\u96c6\u9577",
    "tweet_text": "AstraZeneca's Calquence nabs another win against Imbruvica, but Eli Lilly is on its heels https://t.co/rr2Rh0Xzyz"
  },
  "1353710232245923840": {
    "tweet_author": "Paperbirds_Hematology",
    "tweet_text": "New clinical trial: A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL https://t.co/PcXRdX1RYs #CLL #leusm #hematology"
  },
  "1353709022336200706": {
    "tweet_author": "InvestorsObserver",
    "tweet_text": "$AZN +0.8% (reports Calquence met primary efficacy endpoint in a head-to-head trial against ibrutinib; receives approval in Japan for treatment of relapsed or refractory chronic lymphocytic leukemia) \n\nhttps://t.co/MDjBoLlE4y"
  },
  "1353704850387841024": {
    "tweet_author": "Devdiscourse",
    "tweet_text": "BRIEF-AstraZeneca Says Calquence Approved In Japan For CLL https://t.co/fbGcH4txU4"
  },
  "1353700939681689600": {
    "tweet_author": "Company News HQ",
    "tweet_text": "Calquence met primary efficacy endpoint in head-to-head trial against ibrutinib in chronic lymphocytic leukaemia https://t.co/nY5QWDup8o"
  },
  "1353688716691304448": {
    "tweet_author": "CHItraders",
    "tweet_text": "$AZN AstraZeneca's Calquence successful in lymphocytic leukaemia study https://t.co/9yoennjGjV"
  },
  "1353684379634196480": {
    "tweet_author": "****",
    "tweet_text": "AwesomeCapital: AstraZeneca: Calquence safer than Imbruvica https://t.co/cXEDyLNqvy"
  },
  "1353679151421509633": {
    "tweet_author": "Briefing.com",
    "tweet_text": "$AZN: AstraZeneca reports Calquence met primary efficacy endpoint in head-to-head trial against ibrutinib; recieves... https://t.co/FVIb69NojY"
  },
  "1353678785124700160": {
    "tweet_author": "Quant Data",
    "tweet_text": "AstraZeneca's CALQUENCE Met its Primary Efficacy Endpoint\n\nRelated Tickers: $AZN\nRead more at: https://t.co/2zmD10ekY5"
  },
  "1353676688463458309": {
    "tweet_author": "PharmaTimes",
    "tweet_text": "Calquence tops Imbruvica in chronic lymphocytic leukaemia study https://t.co/rYM3dexyjU #pharmanews #pharma"
  },
  "1353676188158488577": {
    "tweet_author": "OTC Dynamics, Inc.",
    "tweet_text": "$AZN CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia https://t.co/WX6BckCEVX"
  },
  "1353675874667687936": {
    "tweet_author": "Latest News from Business Wire",
    "tweet_text": "CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia https://t.co/FbGmW98yxz https://t.co/5RUxRWogIe"
  },
  "1353675668102410242": {
    "tweet_author": "IMPharma News",
    "tweet_text": "CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia \nhttps://t.co/wW4SyfQmgI"
  },
  "1353675469418192899": {
    "tweet_author": "Crwe World",
    "tweet_text": "CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia https://t.co/Z5lM1bSKso"
  },
  "1353675411935399936": {
    "tweet_author": "AstraZenecaUS",
    "tweet_text": "Today we announced high-level results from the head-to-head ELEVATE-RR Phase III trial in adults with previously treated, high-risk chronic lymphocytic #leukemia. Learn more: https://t.co/KuCUFoV8mT https://t.co/bjLnjYzuBe"
  },
  "1353674732298674178": {
    "tweet_author": "Stock Titan",
    "tweet_text": "$AZN CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia\nhttps://t.co/PcJ2mo27hg"
  },
  "1353670969932578816": {
    "tweet_author": "Gordon Gekko",
    "tweet_text": "AstraZeneca's Calquence successful in lymphocytic leukaemia study https://t.co/E7LKfbW6zG"
  },
  "1353670149241524224": {
    "tweet_author": "Investor News",
    "tweet_text": "AstraZeneca's Calquence successful in lymphocytic leukaemia study $AZN https://t.co/MiKEQaiDX9"
  },
  "1353670085190139904": {
    "tweet_author": "Stocks tweets",
    "tweet_text": "AstraZeneca's Calquence successful in lymphocytic leukaemia study https://t.co/TvIRCguAEg"
  },
  "1353669340336320512": {
    "tweet_author": "Breaking News",
    "tweet_text": "$AZN - AstraZeneca's Calquence successful in lymphocytic leukaemia study https://t.co/tuPuq5E2jw"
  },
  "1353665568767926273": {
    "tweet_author": "Soumyajyoti Biswas",
    "tweet_text": "$AZN\nAstraZeneca's Calquence met primary endpoint in head-to-head trial vs. ibrutinib The company states: \"\"Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca's Calquence, or acalabrutinib, met th... https://t.co/9SExNE4WOx"
  },
  "1353663982821908480": {
    "tweet_author": "pharmaphorum",
    "tweet_text": ".@AstraZeneca says Calquence is less likely to cause atrial fibrillation than J&amp;J and AbbVie's market leading BTK inhibitor Imbruvica; also gets green light for the drug in Japan for relapsed chronic lymphocytic #leukaemia #pharma #oncology https://t.co/ckiwpOqQi0 https://t.co/OAjBYm3tEW"
  },
  "1353663947510067201": {
    "tweet_author": "Shifting Wealth",
    "tweet_text": "AstraZeneca's Calquence approved in Japan for CLL treatment\n$AZN"
  },
  "1353663446005518338": {
    "tweet_author": "dough",
    "tweet_text": "$AZN Calquence head to head study vs Imbruvica in 2L CLL non-inferior PFS with significant reduction in atrial fibrillation."
  },
  "1353662941426561024": {
    "tweet_author": "Shifting Wealth",
    "tweet_text": "AstraZeneca's Calquence met primary endpoint in head-to-head trial vs. ibrutinib\n$AZN"
  },
  "1353655238461251584": {
    "tweet_author": "FinanzLinksRatings",
    "tweet_text": "\u25b6 Goldman bel\u00e4sst Astrazeneca auf 'Sell' - Ziel 6575 Pence: NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung f\u00fcr Astrazeneca angesichts positiver Studiendaten mit dem Medikament Calquence zur Behandlung\u2026 https://t.co/LL9o9N95FN AKTIENCHECK"
  },
  "1353655110618943488": {
    "tweet_author": "FinanzLinksRatings",
    "tweet_text": "\u25b6 dpa-AFX: Goldman bel\u00e4sst Astrazeneca auf 'Sell' - Ziel 6575 Pence: NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung f\u00fcr Astrazeneca angesichts positiver Studiendaten mit dem Medikament Calquence zur\u2026 https://t.co/s4lCqAL59i FINANZTREFF"
  },
  "1353642661132050432": {
    "tweet_author": "PHARMABOX.IN",
    "tweet_text": "Calquence tops Imbruvica in chronic lymphocytic leukaemia study https://t.co/cEd42RpVQ7"
  },
  "1353627828290375680": {
    "tweet_author": "LifeProNow-Pharma-Research and News",
    "tweet_text": "Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia\n\nhttps://t.co/733f9eYYw5 https://t.co/QjihtiREWu"
  },
  "1353624835193249792": {
    "tweet_author": "Josekun",
    "tweet_text": "BRIEF-AstraXeneca Says Calquence Approved In Japan For CLL https://t.co/34S4wNhMwz"
  },
  "1353624833263853568": {
    "tweet_author": "Josekun",
    "tweet_text": "AstraZeneca's leukaemia treatment wins approval in Japan; Calquence meets primary goal https://t.co/qIzMgrqDqg"
  },
  "1353622517492101120": {
    "tweet_author": "Jan Ehses",
    "tweet_text": "$AZN https://t.co/9QBjQ7D59e"
  },
  "1353621966612287488": {
    "tweet_author": "Jan Ehses",
    "tweet_text": "$AZN https://t.co/xiEvIrVgUT"
  },
  "1353620686456188928": {
    "tweet_author": "Kevin Jacobs \ud83c\udde7\ud83c\uddea \ud83c\uddf5\ud83c\uddf1 \ud83c\uddee\ud83c\uddf9 \ud83c\uddea\ud83c\uddfa",
    "tweet_text": "$AZN Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia"
  },
  "1353618566906523648": {
    "tweet_author": "Golden Casino News",
    "tweet_text": "Calquence met primary endpoint against ibrutinib - https://t.co/3dNw2je6hX"
  },
  "1353618563358195714": {
    "tweet_author": "Golden Casino News",
    "tweet_text": "Calquence approved in Japan for CLL - https://t.co/aY94hrR2MF"
  },
  "1353618367190605824": {
    "tweet_author": "Kevin Jacobs \ud83c\udde7\ud83c\uddea \ud83c\uddf5\ud83c\uddf1 \ud83c\uddee\ud83c\uddf9 \ud83c\uddea\ud83c\uddfa",
    "tweet_text": "$AZN Calquence Met Primary Endpoint Against Ibrutinib\n\n*MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB IN CHRONIC LYMPHOCYTIC\nLEUKAEMIA\n\n*SUPERIOR SAFETY ON KEY SECONDARY ENDPOINT OF ATRIAL FIBRILLATION"
  },
  "1353615905092218882": {
    "tweet_author": "Sharecast.com",
    "tweet_text": "AstraZeneca reports positive test results, new approval for 'Calquence' https://t.co/mKjcgptvio"
  },
  "1353613727287930880": {
    "tweet_author": "EIN Presswire: Pharmaceutical Newswire",
    "tweet_text": "AstraZeneca's leukaemia treatment wins approval in Japan; Calquence meets primary goal https://t.co/Itc96p09KP"
  },
  "1353608619133181952": {
    "tweet_author": "Value's Vector",
    "tweet_text": "LiveSquawk: $AZN | AstraZeneca Plc - Calquence Met Primary Endpoint Against Ibrutinib\nCalquence Met Primary Efficacy Endpoint In Head-To-Head Trial Against Ibrutinib In Chronic Lymphocytic Leukaemia"
  },
  "1353605487414149120": {
    "tweet_author": "Devdiscourse",
    "tweet_text": "BRIEF-AstraXeneca Says Calquence Approved In Japan For CLL https://t.co/JJwbaalBwL"
  },
  "1353603371576537088": {
    "tweet_author": "Devdiscourse",
    "tweet_text": "BRIEF-AstraZeneca Says Calquence Met Primary Endpoint Against Ibrutinib https://t.co/PuDcymtl77"
  },
  "1353602178171211777": {
    "tweet_author": "Mathan",
    "tweet_text": "$AZN | ASTRAZENECA PLC - CALQUENCE MET PRIMARY ENDPOINT AGAINST IBRUTINIB\nCALQUENCE MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKAEMIA"
  },
  "1353601006378971138": {
    "tweet_author": "Cision News",
    "tweet_text": "Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia https://t.co/VxTrombric"
  },
  "1353601002541203456": {
    "tweet_author": "Cision News",
    "tweet_text": "Calquence approved in Japan for CLL https://t.co/LivCdCnSXj"
  },
  "1353600269460926464": {
    "tweet_author": "Company News HQ",
    "tweet_text": "Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia https://t.co/8brx5cBNuQ"
  },
  "1353599509071183872": {
    "tweet_author": "Cision News",
    "tweet_text": "Calquence met primary efficacy endpoint in head-to-head trial against ibrutinib in chronic lymphocytic leukaemia https://t.co/E4z0jbbJCH"
  },
  "1353599366431268867": {
    "tweet_author": "Cision News",
    "tweet_text": "Calquence met primary endpoint against ibrutinib https://t.co/nb9inloykE"
  },
  "1353599249263579136": {
    "tweet_author": "LiveSquawk",
    "tweet_text": "$AZN | AstraZeneca Plc - Calquence Met Primary Endpoint Against Ibrutinib\nCalquence Met Primary Efficacy Endpoint In Head-To-Head Trial Against Ibrutinib In Chronic Lymphocytic Leukaemia"
  },
  "1353593704649347072": {
    "tweet_author": "TYR Kinase papers",
    "tweet_text": "The European Medicines Agency Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia https://t.co/ZdByIV9NGy"
  },
  "1351871111802155009": {
    "tweet_author": "Paperbirds_Hematology",
    "tweet_text": "New clinical trial: Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) https://t.co/S9yRtWE5LY #MCL #lymsm #hematology"
  },
  "1351870476574810114": {
    "tweet_author": "Paperbirds_Hematology",
    "tweet_text": "New clinical trial: Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) https://t.co/bVSRWzHwbx #CLL #leusm #hematology"
  },
  "1351038803448889352": {
    "tweet_author": "Health Radio Online",
    "tweet_text": "AstraZeneca's New CALQUENCE\u00ae Data in Mantle Cell Lymphoma (MCL)\nRead more: https://t.co/AaHAiq55rn\n#CALQUENCE #ASH2020 #MantleCellLymphoma"
  },
  "1350884999151693824": {
    "tweet_author": "Medivizor",
    "tweet_text": "Check out: Comparing acalabrutinib to standard treatments in patients with chronic ly... https://t.co/tLXIunsT1a via @medivizor #Leukemia"
  },
  "1350472994313756673": {
    "tweet_author": "Aaron Goodman - \u201cPapa Heme\u201d",
    "tweet_text": "This is what happens when you let oncologists design trials for a viral infection.  The following therapies are/were being tested in COVID19 trials\n\nRuxolitinib\nEtoposide\nIbrutinib\nSelinexor\nLenalidomide\nAcalabrutinib\nBaricitinib\nZanabrutinib\nChest radiation"
  },
  "1349838759966216193": {
    "tweet_author": "CADTH",
    "tweet_text": "CADTH has issued a final recommendation that #acalabrutinib\n(#Calquence) be reimbursed with clinical criteria and/or conditions for the treatment of Chronic lymphocytic #leukemia (previously untreated). \n\nRead the full recommendation here: https://t.co/dAB8GavDdc https://t.co/z6zFvD33Nw"
  },
  "1349688957332811776": {
    "tweet_author": "Toby Eyre",
    "tweet_text": "Great to continue to recruit into the first ever randomised 1L trial in #Richters transformation\n\nRCHOP vs RCHOP+acalabrutinib\n\nWe are a quarter of the way there! #lymsm #CLL @OUH_Research @AnnaSchuh3 https://t.co/Dvl7pnO5OY"
  },
  "1348968100910260225": {
    "tweet_author": "Lymphoma Papers",
    "tweet_text": "Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. #lymphoma #lymsm https://t.co/VNtOJXBAl1"
  },
  "1348948980126814208": {
    "tweet_author": "Paperbirds_Hematology",
    "tweet_text": "New article: Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. https://t.co/aa3xLPsM57 #CLL #leusm #hematology"
  },
  "1348738438787379200": {
    "tweet_author": "Medivizor",
    "tweet_text": "Learn more: Comparing acalabrutinib to standard treatments in patients with chroni... https://t.co/tLXIunsT1a #Leukemia (via @medivizor)"
  },
  "1348520236249710596": {
    "tweet_author": "Top News Corner",
    "tweet_text": "New post (Acalabrutinib Market Report, Size, Key Players And Global Forecast to 2025) has been published on https://t.co/fdzRB6KRVD - https://t.co/5tIxXQsJ3c https://t.co/fIrPpYDHI0"
  },
  "1347474172008665089": {
    "tweet_author": "Pharmazeutische Zeitung",
    "tweet_text": "Mit Acalabrutinib kam im Dezember ein neuer Bruton-Tyrosinkinase(BTK)-Hemmer auf den Markt. Der Neuling wird wie das seit 2014 verf\u00fcgbare Ibrutinib peroral bei Patienten mit chronisch lymphatischer #Leuk\u00e4mie eingesetzt https://t.co/Jjqy1XCUAM"
  },
  "1347472919660781575": {
    "tweet_author": "RS6",
    "tweet_text": "https://t.co/XTWA2Bz5NB"
  },
  "1347180984190595083": {
    "tweet_author": "Amar Bhandari",
    "tweet_text": "Global Acalabrutinib Market In-Depth Analysis Report\u00a02020 https://t.co/nX3NfUKGFB"
  },
  "1347070826491817984": {
    "tweet_author": "Industry News Engine",
    "tweet_text": "Acalabrutinib Market Report Till 2025 | Global Manufacturers\u00a0Analysis https://t.co/T1442apiD3"
  },
  "1345837516667154434": {
    "tweet_author": "Targeted Oncology",
    "tweet_text": "\u201cThe PFS for patients in the acalabrutinib arms [of the ELEVATE CLL TN trial] outperformed the control, which was obinutuzumab/chlorambucil, by a significant difference,\u201d Dr. Seymour said during this live virtual meeting.\nhttps://t.co/OZz2ovjCLE #leukemia"
  },
  "1345374991446134786": {
    "tweet_author": "Medicina e Informazione",
    "tweet_text": "Leucemia linfatica cronica: acalabrutinib \u00e8 approvato in Europa. Ha dimostrato un beneficio significativo in termini di efficacia e tollerabilit\u00e0 a lungo termine tanto nel trattamento in prima linea quanto nella malattia recidivante o refrattaria\nhttps://t.co/R1CPilGRTH https://t.co/TqKhOuaiUP"
  },
  "1344870978896101376": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqqbUX8 CALQUENCE is an oral treatment option for adult patients with chronic lymphocytic leukemia (CLL)."
  },
  "1344870978480865281": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqqbUX8 See if CALQUENCE can be used to treat your adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)."
  },
  "1344870977759371266": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqqbUX8 In a study of 535 chronic lymphocytic leukemia (CLL) patients, 1L CALQUENCE+obinutuzumab demonstrated 90% relative risk reduction (HR=0.10[95% CI: 0.06-0.17], P&lt;0.001) in disease progression or death vs GCIb (obinutuzumab+chlorambucil)."
  },
  "1344870977100910593": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqqbUX8 In a study of 535 chronic lymphocytic leukemia (CLL) patients, 1L CALQUENCE+obinutuzumab demonstrated 90% relative risk reduction (HR=0.10[95% CI: 0.06-0.17], P&lt;0.001) in disease progression or death vs GCIb (obinutuzumab+chlorambucil)."
  },
  "1344870976811487234": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqqbUX8 In a study of 535 chronic lymphocytic leukemia (CLL) patients, 1L CALQUENCE+obinutuzumab demonstrated 90% relative risk reduction (HR=0.10[95% CI: 0.06-0.17], P&lt;0.001) in disease progression or death vs GCIb (obinutuzumab+chlorambucil)."
  },
  "1344870975888879623": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A In a study of 535 chronic lymphocytic leukemia (CLL) patients, 1L CALQUENCE+obinutuzumab demonstrated 90% relative risk reduction (HR=0.10[95% CI: 0.06-0.17], P&lt;0.001) in disease progression or death vs GCIb (obinutuzumab+chlorambucil)."
  },
  "1344870975809101825": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqqbUX8 CALQUENCE is an oral treatment option for adult patients with chronic lymphocytic leukemia (CLL)."
  },
  "1344870975049908227": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqqbUX8 In a study of 535 chronic lymphocytic leukemia (CLL) patients, 1L CALQUENCE+obinutuzumab demonstrated 90% relative risk reduction (HR=0.10[95% CI: 0.06-0.17], P&lt;0.001) in disease progression or death vs GCIb (obinutuzumab+chlorambucil)."
  },
  "1344870974571819009": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A See if CALQUENCE can be used to treat your adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)."
  },
  "1344870972692836352": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A See if CALQUENCE can be used to treat your adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)."
  },
  "1344870972063531008": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqqbUX8 In a study of 535 chronic lymphocytic leukemia (CLL) patients, 1L CALQUENCE+obinutuzumab demonstrated 90% relative risk reduction (HR=0.10[95% CI: 0.06-0.17], P&lt;0.001) in disease progression or death vs GCIb (obinutuzumab+chlorambucil)."
  },
  "1344870969492578304": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A CALQUENCE is an oral treatment option for adult patients with chronic lymphocytic leukemia (CLL)."
  },
  "1344340117452894210": {
    "tweet_author": "Joseph Cioccio, DO",
    "tweet_text": "Why might a person with CLL be anemic?\n1) BM involved (Rai III). Dx - BM Bx\nTx = venetoclax/obinutuzumab or acalabrutinib +/- obinu\nFCR*\n\n2) AIHA- DX- DAT, \u2b06\ufe0f t bili, \u2b06\ufe0fldh, \u2b07\ufe0fhapto, \u2b06\ufe0f retic\nTx roids if fail then as above\n\n3) PRCA, \u2b07\ufe0f retics, \nTx = IST\n\n#Cioc_edu /1"
  },
  "1344068316353228809": {
    "tweet_author": "CureHuntr",
    "tweet_text": "#clinicaltrial Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. https://t.co/l6wzhD0nPv"
  },
  "1343991464515301385": {
    "tweet_author": "VJHemOnc",
    "tweet_text": "#Zanubrutinib for ibrutinib/acalabrutinib intolerant R/R B-cell malignancies w/ Ian Flinn of @SarahCannonDocs: https://t.co/jvPhvqOlus\n\n#ASH20 @ASH_hematology #HemOnc #Leusm #Leukemia #CLLsm #CTsm"
  },
  "1343959049902182400": {
    "tweet_author": "TrialBulletin",
    "tweet_text": "Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.: Status: Not yet recruiting, \nCondition Summary: Primary Central Nervous System Lymphoma (PCNSL) https://t.co/SfBdbbIt6n"
  },
  "1343937359734304768": {
    "tweet_author": "OncLive SOSS",
    "tweet_text": ".@SeemaAliBhat1 of @OSUCCC_James discusses the rationale to evaluate #acalabrutinib in chronic lymphocytic leukemia #CLL\nhttps://t.co/rTGycOO6dq https://t.co/LtNBss74zI"
  },
  "1343180063504740353": {
    "tweet_author": "Targeted Oncology",
    "tweet_text": "\u201cThe PFS for patients in the acalabrutinib arms [of the ELEVATE CLL TN trial] outperformed the control, which was obinutuzumab/chlorambucil, by a significant difference,\u201d Dr. Seymour, of @karmanoscancer, said in this live virtual meeting.\nhttps://t.co/OZz2ovjCLE #CLL #leusm"
  },
  "1342866355868086272": {
    "tweet_author": "Medivizor",
    "tweet_text": "New: Comparing acalabrutinib to standard treatments in patients with chronic lymphocy... https://t.co/tLXIunsT1a via @medivizor #Leukemia"
  },
  "1342203098220130304": {
    "tweet_author": "DRUGDOCS",
    "tweet_text": "#Calquence Product Monograph, Prescribing Info, Health Technology Assessments and More! \n\nAccess Drug Documents \ud83d\udc47"
  },
  "1342151826670571522": {
    "tweet_author": "Oncology Nursing News",
    "tweet_text": "In case you missed it: Patients with CLL who received treatment with single-agent acalabrutinib experienced a low incidence of cardiac toxicities, according to data from a pooled analysis across 4 clinical trials. https://t.co/cx3xGOuIh8"
  },
  "1340952146997460994": {
    "tweet_author": "EmatoInfo",
    "tweet_text": "#ASH20 | Nuove importanti conferme sull\u2019utilizzo di #acalabrutinib in combinazione nel trattamento della leucemia linfatica cronica, con risultati significativi in termini di risposta completa e MRD negativit\u00e0. Le parole di Francesca Romana Mauro. https://t.co/srgFXxx2Ts"
  },
  "1340823055371816960": {
    "tweet_author": "Oncology Nursing News",
    "tweet_text": "Patients with CLL who received treatment with single-agent acalabrutinib experienced a low incidence of cardiac toxicities, according to data from a pooled analysis across 4 clinical trials. https://t.co/cx3xGOuIh8"
  },
  "1340738181398982657": {
    "tweet_author": "Medivizor",
    "tweet_text": "Check out Comparing acalabrutinib to standard treatments in patients with chronic lym... https://t.co/tLXIunsT1a via @medivizor #Leukemia"
  },
  "1339918478950756355": {
    "tweet_author": "OncLive.com",
    "tweet_text": "Results showed that 17% of 762 patients with CLL who received treatment with the 2nd generation BTK inhibitor as a monotherapy experienced cardiac toxicity of any grade at a median follow-up of 25.9 months. @ASH_hematology #ASH20 https://t.co/PyX4eZaZC3"
  },
  "1339578709846732800": {
    "tweet_author": "pharmanewsintel",
    "tweet_text": "AstraZeneca's Phase 2 #clinicaltrial found that multiple cell lymphoma patients treated with AstraZeneca\u2019s #cancerdrug, Calquence, remained progression free for an average of 22 months. \n\nhttps://t.co/C5Xxpxjt8n"
  },
  "1339432645084684289": {
    "tweet_author": "JPubb \u65e5\u672c\u4f01\u696d \u30ea\u30ea\u30fc\u30b9 \u533b\u85ac\u54c1",
    "tweet_text": "\u30a2\u30b9\u30c8\u30e9\u30bc\u30cd\u30ab\u306e\u30a2\u30ab\u30e9\u30d6\u30eb\u30c1\u30cb\u30d6\uff08Calquence\u00ae\uff09\u30014\u3064\u306e\u8a66\u9a13\u30c7\u30fc\u30bf\u306b\u3088\u3063\u3066\u3001\u6162\u6027\u30ea\u30f3\u30d1\u6027\u767d\u8840\u75c5\u306e\u60a3\u8005\u3055\u3093\u306e\u5fc3\u8840\u7ba1\u5b89\u5168\u6027\u30d7\u30ed... \u301412/17 \u30a2\u30b9\u30c8\u30e9\u30bc\u30cd\u30ab\u3015 https://t.co/isvqYLMTWE"
  },
  "1339400282984214528": {
    "tweet_author": "PR TIMES\u30d3\u30b8\u30cd\u30b9",
    "tweet_text": "\u30a2\u30b9\u30c8\u30e9\u30bc\u30cd\u30ab\u306e\u30a2\u30ab\u30e9\u30d6\u30eb\u30c1\u30cb\u30d6\uff08Calquence\u00ae\uff09\u30014\u3064\u306e\u8a66\u9a13\u30c7\u30fc\u30bf\u306b\u3088\u3063\u3066\u3001\u6162\u6027\u30ea\u30f3\u30d1\u6027\u767d\u8840\u75c5\u306e\u60a3\u8005\u3055\u3093\u306e\u5fc3\u8840... https://t.co/UAxtcYBcaN"
  },
  "1339392438775894018": {
    "tweet_author": "PR TIMES\u30cb\u30e5\u30fc\u30b9",
    "tweet_text": "\u30a2\u30b9\u30c8\u30e9\u30bc\u30cd\u30ab\u306e\u30a2\u30ab\u30e9\u30d6\u30eb\u30c1\u30cb\u30d6\uff08Calquence\u00ae\uff09\u30014\u3064\u306e\u8a66\u9a13\u30c7\u30fc\u30bf\u306b\u3088\u3063\u3066\u3001\u6162\u6027\u30ea\u30f3\u30d1\u6027\u767d\u8840\u75c5\u306e\u60a3\u8005\u3055\u3093\u306e\u5fc3\u8840... https://t.co/1BZ6NYUWon"
  },
  "1339390406853881857": {
    "tweet_author": "WMR Tokyo - \u30b9\u30bf\u30fc\u30c8\u30a2\u30c3\u30d7",
    "tweet_text": "\u30a2\u30b9\u30c8\u30e9\u30bc\u30cd\u30ab\u306e\u30a2\u30ab\u30e9\u30d6\u30eb\u30c1\u30cb\u30d6\uff08Calquence(R)\uff09\u30014\u3064\u306e\u8a66\u9a13\u30c7\u30fc\u30bf\u306b\u3088\u3063\u3066\u3001\u6162\u6027\u30ea\u30f3\u30d1\u6027\u767d\u8840\u75c5\u306e\u60a3\u8005\u3055\u3093\u306e\u5fc3\u8840\u7ba1\u5b89\u5168\u6027\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3092\u8a55\u4fa1 https://t.co/rwagDQt79P"
  },
  "1339337448543883267": {
    "tweet_author": "Ashleigh Walls",
    "tweet_text": "Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It\u2019s a prescription oral 2x a day capsule. Learn more: https://t.co/BuFOYoX5iY #bloodcancerawareness #ad https://t.co/TjcmlppbWN https://t.co/XSJy81zZGo"
  },
  "1339280070196621312": {
    "tweet_author": "bargainbriana",
    "tweet_text": "Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients with CLL. https://t.co/olbLAT1iul #bloodcancerawareness #ad https://t.co/IN8KmIDSIN https://t.co/21brOD585J"
  },
  "1339275381170348032": {
    "tweet_author": "April Golightly",
    "tweet_text": "Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It\u2019s a prescription oral 2x a day capsule. Learn more: https://t.co/uzjsIfXTb9 #bloodcancerawareness #ad https://t.co/613omF99rh https://t.co/M6FMVHOT2h"
  },
  "1339165345291112449": {
    "tweet_author": "dough",
    "tweet_text": "$AZN LR OP Multiple best-in-class oncology portfolio deserves premium Oncology portfolio includes multiple potentially best-in-class assets, including Tagrisso, Lynparza, Calquence, Enhertu, and Imfinzi https://t.co/KFiGbg5jvi"
  },
  "1339017286653448192": {
    "tweet_author": "jorge",
    "tweet_text": "Cancer drug as COVID-19 treatment scrapped from WHO Solidarity Trials https://t.co/isO9vJe4js"
  },
  "1338970852617019393": {
    "tweet_author": "iSanidad",
    "tweet_text": "#Investigaci\u00f3n \ud83d\udd0e | Los datos de #acalabrutinib de 4 ensayos cl\u00ednicos refuerzan su perfil de seguridad cardiovascular en pacientes con #leucemia linfoc\u00edtica cr\u00f3nica @AstraZenecaES \n\nhttps://t.co/c60KOMIBJt"
  },
  "1338857609542201344": {
    "tweet_author": "iSanidad",
    "tweet_text": "\ud83d\udd0e Los datos de #acalabrutinib de 4 ensayos cl\u00ednicos refuerzan su perfil de seguridad cardiovascular en pacientes con #leucemia linfoc\u00edtica cr\u00f3nica @AstraZenecaES \n\nhttps://t.co/c60KOMIBJt"
  },
  "1338710401790472194": {
    "tweet_author": "OncLive.com",
    "tweet_text": "Patients with CLL who received treatment with single-agent acalabrutinib experienced a low incidence of cardiac toxicities leading to treatment discontinuation. @ASH_hematology #ASH20 https://t.co/1bPqyNA0km"
  },
  "1338662943920152578": {
    "tweet_author": "Trip Database",
    "tweet_text": "New2Trip: Acalabrutinib (Calquence) - chronic lymphocytic leukaemia (CLL) https://t.co/u3lRYIvDfK"
  },
  "1338620216897544192": {
    "tweet_author": "Radyo La Verdad 1350",
    "tweet_text": "Kinumpirma ng Department of Health na hindi na gagamitin sa World Health Organization solidarity trial ng therapeutics o mga gamot ang Acalabrutinib. https://t.co/FwV4nC5tzT"
  },
  "1338531756996255753": {
    "tweet_author": "CURE Magazine",
    "tweet_text": "At a median follow-up of 25.9 months, 17% of the patient population who received Calquence monotherapy experienced a cardiac toxicity of any severity, which led to treatment discontinuation in only seven patients. https://t.co/w4nltTQFJF"
  },
  "1338498441358405634": {
    "tweet_author": "Radyo La Verdad 1350",
    "tweet_text": "Acalabrutinib, hindi na gagamitin sa WHO solidarity trial ng therapeutic... https://t.co/FwV4nC5tzT via @YouTube"
  },
  "1338438148410392578": {
    "tweet_author": "Ronald M. Chavin",
    "tweet_text": "12-14-2020: In a decision announced today by the WHO, bad news for AstraZeneca's blood cancer drug, Calquence (acalabrutinib), for treating COVID-19. AstraZeneca had already announced the failure of Calquence\nhttps://t.co/8JwlIjSHTd\nhttps://t.co/AsPNYOtAlF\nhttps://t.co/HFq8FoNQgc"
  },
  "1338432117890420737": {
    "tweet_author": "UNTV News and Rescue",
    "tweet_text": "Acalabrutinib, hindi na gagamitin sa WHO solidarity trial ng therapeutics - DOH  https://t.co/RwKcivPg1p"
  },
  "1338395721079300103": {
    "tweet_author": "DZBB Super Radyo",
    "tweet_text": "5 pasyente, nakumpleto na ang clinical trial ng Avigan bilang gamot sa COVID-19 sa Pilipinas; clinical trial ng cancer drug na Acalabrutinib sa paghanap ng gamot kontra COVID-19, hindi na itinuloy ng @WHO. #SuperBalitaSaHapon https://t.co/Jl7zdrja0g"
  },
  "1338371914142724096": {
    "tweet_author": "Radyo Agila DZEC 1062 Khz",
    "tweet_text": "Cancer drug na Acalabrutinib,inalis na sa mga gamot na kasama sa WHO solidarity trial https://t.co/PxANQ5oOIa"
  },
  "1338368964011782146": {
    "tweet_author": "CNN Philippines",
    "tweet_text": "'Nagbigay na ng recommendation ang WHO. It's not going to be part of the Solidarity Trial anymore,' DOH spokesperson Maria Rosario Vergeire says. https://t.co/BogahKfYMH"
  },
  "1338344742917009410": {
    "tweet_author": "DZBB Super Radyo",
    "tweet_text": "Paggamit ng cancer drug na Acalabrutinib bilang bahagi ng solidarity trial sa paghanap ng gamot para sa COVID-19, hindi na itinuloy ng World Health Organization o @WHO. | via @Isa_Umali"
  },
  "1337659087585239042": {
    "tweet_author": "Medivizor",
    "tweet_text": "NEW: Comparing acalabrutinib to standard treatments in patients with chronic lymphocy... https://t.co/tLXIunsT1a via @medivizor #Leukemia"
  },
  "1337449313648205825": {
    "tweet_author": "This Messy Season Family Blog",
    "tweet_text": "Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It\u2019s a prescription oral 2x a day capsule. Learn more: https://t.co/VRIqUhrkFf. #bloodcancerawareness #ad https://t.co/Y2lMRkOR9k https://t.co/kTaDjk7PUW"
  },
  "1337235679139557387": {
    "tweet_author": "\u5370\u5ea6\u5b5f\u52a0\u62c9\u6297\u764c\u836f",
    "tweet_text": "\u963f\u5361\u66ff\u5c3c \u5b5f\u52a0\u62c9\u8000\u54c1\u56fd\u9645\u9996\u4eff\uff0c\n\u7528\u4e8e\u6cbb\u7597\u60a3\u6709\u5957\u7ec6\u80de\u6dcb\u5df4\u7624\uff08mantlecell lymphoma\uff09\u4e14\u66fe\u63a5\u53d7\u8fc7\u81f3\u5c11\u4e00\u6b21\u6cbb\u7597\u7684\u6210\u4eba\u60a3\u8005\u3002\u63a5\u53d7Calquence\u6cbb\u7597\u7684\u60a3\u8005\u670981%\u83b7\u5f97\u4e86\u5b8c\u5168\u7f13\u89e3\u6216\u90e8\u5206\u7f13\u89e3\n\n\u5242\u578b/\u7ed9\u836f\u9014\u5f84\uff1a\u53e3\u670d\n\n\u4f5c\u7528\u673a\u5236\uff1a\u916a\u6c28\u9178\u6fc0\u9176BTK\u6291\u5236\u5242\uff0c\u963b\u65ad\u764c\u7ec6\u80de\u589e\u6b96\u548c\u6269\u6563\u6240\u9700\u8981\u7684\u9176 https://t.co/B01z5Puj4x"
  },
  "1337155558802038784": {
    "tweet_author": "Cook Eat Go",
    "tweet_text": "#ad Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It\u2019s a prescription oral 2x a day capsule. Learn more: https://t.co/PkC83TF1kq. #bloodcancerawareness https://t.co/7v16qKmdS5 https://t.co/P0jIZK4Jo4"
  },
  "1337102287299350531": {
    "tweet_author": "IM M\u00e9dico",
    "tweet_text": "Los datos de Calquence de 4 ensayos cl\u00ednicos refuerzan su perfil de seguridad cardiovascular en pacientes con LLC\n https://t.co/Sz0v1TRM6K"
  },
  "1337063133286948866": {
    "tweet_author": "William V. Sweeney",
    "tweet_text": "Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients. https://t.co/7q8vWzSwbS #bloodcancerawareness #ad https://t.co/FfjjEHSkg8 https://t.co/IYA4qtCD9F"
  },
  "1337041689567846400": {
    "tweet_author": "Caryn Bailey",
    "tweet_text": "Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/FRgJjnX8v5 #bloodcancerawareness #ad https://t.co/uFYQJrBgZt https://t.co/SyejqJn1a8"
  },
  "1336828570585468930": {
    "tweet_author": "Christi B",
    "tweet_text": "With @CALQUENCE, feel supported all day and night with patient and caregiver resources. CALQUENCE is an oral, 2x a day prescription medication to treat adult patients with CLL or SLL. Learn more at [https://t.co/Ay3QXBPHkk]. #bloodcancerawareness #ad https://t.co/o9G2s6XEMh https://t.co/1AiGr7uzIf"
  },
  "1336828362405392387": {
    "tweet_author": "Trip Database",
    "tweet_text": "New2Trip: 17p deletion testing for access to acalabrutinib in patients w/ relapsed or refractory chronic lymphocytic leukaemia https://t.co/3vVU2IFbFi"
  },
  "1336799465726996486": {
    "tweet_author": "Kami Allen",
    "tweet_text": "Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/9AavBCJUDc #bloodcancerawareness #ad https://t.co/QUI6rhtA06 https://t.co/3914nA0gz5"
  },
  "1336785315873230849": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqqbUX8 Learn more about the demonstrated safety and tolerability profile of CALQUENCE."
  },
  "1336785315864879106": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqqbUX8 Learn more about the demonstrated safety and tolerability profile of CALQUENCE."
  },
  "1336785315827130369": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Don\u2019t miss AstraZeneca\u2019s big reveal of CALQUENCE patient data at this year\u2019s virtual conference!"
  },
  "1336785315814522882": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqqbUX8 Learn more about the demonstrated safety and tolerability profile of CALQUENCE."
  },
  "1336785315793575936": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Don\u2019t miss AstraZeneca\u2019s big reveal of CALQUENCE patient data at this year\u2019s virtual conference!"
  },
  "1336785192141393923": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE."
  },
  "1336785192040747009": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Don\u2019t miss AstraZeneca\u2019s big reveal of CALQUENCE patient data at this year\u2019s virtual conference!"
  },
  "1336785191663251459": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A This year\u2019s all-virtual ASH 2020 conference featured clinical data about CALQUENCE\u2014a treatment option for adults with CLL."
  },
  "1336785191654871041": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE."
  },
  "1336785191554097152": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqqbUX8 Learn more about the demonstrated safety and tolerability profile of CALQUENCE."
  },
  "1336785191163973632": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqqbUX8 Learn more about the demonstrated safety and tolerability profile of CALQUENCE."
  },
  "1336785190929264644": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE."
  },
  "1336785190753095682": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE."
  },
  "1336785190753079296": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE."
  },
  "1336785190719393793": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Don\u2019t miss AstraZeneca\u2019s big reveal of CALQUENCE patient data at this year\u2019s virtual conference!"
  },
  "1336785190631436288": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE."
  },
  "1336785190404956160": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Don\u2019t miss AstraZeneca\u2019s big reveal of CALQUENCE patient data at this year\u2019s virtual conference!"
  },
  "1336785190316699649": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqqbUX8 Learn more about the demonstrated safety and tolerability profile of CALQUENCE."
  },
  "1336785190211895297": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqqbUX8 Don\u2019t miss Dr Michael Wang present AstraZeneca\u2019s clinical data from CALQUENCE at this year\u2019s virtual conference!"
  },
  "1336785190174199815": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Don\u2019t miss AstraZeneca\u2019s big reveal of CALQUENCE patient data at this year\u2019s virtual conference!"
  },
  "1336785189964455936": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqqbUX8 Learn more about the demonstrated safety and tolerability profile of CALQUENCE."
  },
  "1336749685801775106": {
    "tweet_author": "Coralie Seright (Lovebugs and Postcards)",
    "tweet_text": "Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients with CLL. https://t.co/T31Tzi5GEc #bloodcancerawareness #ad https://t.co/koo80IGjvP https://t.co/vKF60hrjUH"
  },
  "1336740572594376704": {
    "tweet_author": "Elizabeth hurt",
    "tweet_text": "Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. Calquence is a prescription treatment option for adult patients with CLL. https://t.co/bcU1EB38YM #bloodcancerawareness #ad https://t.co/cMWmUTldVy https://t.co/FIz6xlQ8Fg"
  },
  "1336729956869615616": {
    "tweet_author": "EmatoInfo",
    "tweet_text": "#ASH20 | Leucemia linfatica cronica: il trattamento con acalabrutinib in monoterapia si caratterizza per l\u2019ottimo profilo di safety, elemento assolutamente decisivo nell'ambito di questa patologia. L'intervista a Paolo Ghia [@SanRaffaeleMI]. \nhttps://t.co/dTzv6l09cP"
  },
  "1336713314227851264": {
    "tweet_author": "Benlazar S.M Amin\u00e9",
    "tweet_text": "Acalabrutinib+R-CHOP in ND #DLBCL #ASH20 https://t.co/hReK2IngxX"
  },
  "1336711180967178243": {
    "tweet_author": "Benlazar S.M Amin\u00e9",
    "tweet_text": "Acalabrutinib in R/R MCL #ASH20 https://t.co/jwz3TLIwxs"
  },
  "1336710567118184449": {
    "tweet_author": "Benlazar S.M Amin\u00e9",
    "tweet_text": "Acalabrutinib cost effectiveness #ASH20 https://t.co/IF9eYVa8in"
  },
  "1336709163326574596": {
    "tweet_author": "Benlazar S.M Amin\u00e9",
    "tweet_text": "Acalabrutinib cardiovascular events #ASH20 https://t.co/ilBGhugwz7"
  },
  "1336705401933492226": {
    "tweet_author": "Benlazar S.M Amin\u00e9",
    "tweet_text": "AVO (Acalabrutinib, Venettoclax + R/O in R/R #CLL #ASH20 https://t.co/MgetA1UgG3"
  },
  "1336666415848333313": {
    "tweet_author": "Paperbirds_Hematology",
    "tweet_text": "New clinical trial: Early Intervention With Acalabrutinib in Patients With High Risk CLL https://t.co/nH9vPENaFS #CLL #leusm #hematology"
  },
  "1336658622110027776": {
    "tweet_author": "Pepvax Inc",
    "tweet_text": "Acalabrutinib Demonstrates Low Cardiac Risk in Chronic Lymphocytic Leukemia - Targeted Oncology https://t.co/ICvz09sP1F https://t.co/s5EOD1ivwm"
  },
  "1336641406111191042": {
    "tweet_author": "pharmaphorum",
    "tweet_text": "NHS England is to grant immediate access to cancer drug Calquence from @AstraZeneca for certain patients with chronic lymphocytic leukaemia (CLL) after NICE backed it in first draft recommendations https://t.co/TDeYEDncwj #cancer #pharma"
  },
  "1336596452152385536": {
    "tweet_author": "NICE",
    "tweet_text": "NICE has recommended the use of acalabrutinib for certain adults with untreated and treated chronic lymphocytic leukaemia. Read the draft guidance and take part in the consultation until Monday 11 January 2021, at: https://t.co/QRGsgACUdd https://t.co/IDZTWq5Bhk"
  },
  "1336546474042200065": {
    "tweet_author": "mednetnews",
    "tweet_text": "Acalabrutinib Demonstrates Low Cardiac Risk in Chronic Lymphocytic Leukemia | Targeted\u00a0Oncology https://t.co/xwPSwP0ij8"
  },
  "1336503842259800064": {
    "tweet_author": "Bionest Partners",
    "tweet_text": "AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice. After demonstrating positive long-term efficacy and tolerability in #MCL, does this open the door for Calquence in #CLL? https://t.co/tXiWpyegNP https://t.co/8GvCMTXMRB"
  },
  "1336439052833337347": {
    "tweet_author": "Lisa O'Driscoll",
    "tweet_text": "Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients with CLL. https://t.co/v46unah7p2 #bloodcancerawareness #ad https://t.co/DljdCKTD7E https://t.co/aQD1ULX1AC"
  },
  "1336412717322825728": {
    "tweet_author": "Tamara Bowman",
    "tweet_text": "Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It\u2019s a prescription oral 2x a day capsule. Learn more: https://t.co/ejeIHp0kp4. #bloodcancerawareness #ad https://t.co/dYU8rG364A https://t.co/Yr152q3fYx"
  },
  "1336400417656164352": {
    "tweet_author": "David Ledger",
    "tweet_text": "NICE backs AZ' Calquence for chronic lymphocytic leukaemia https://t.co/lMXJbU0JHb https://t.co/77CPBuyHR5"
  },
  "1336398436179054594": {
    "tweet_author": "Benlazar S.M Amin\u00e9",
    "tweet_text": "Management of Waldenstr\u00f6m Macroglobulinemia in 2020: Acalabrutinib and Zanubrutinib #ASH20 https://t.co/ApLKP8w2tt"
  },
  "1336359899522080768": {
    "tweet_author": "Plexus Ventures",
    "tweet_text": "NICE backs #AstraZeneca #Calquence for chronic lymphocytic #leukaemia https://t.co/Js1rSgNnsG @PharmaTimes @AstraZeneca #CLL"
  },
  "1336346700202594304": {
    "tweet_author": "Pharmafocus",
    "tweet_text": "NICE recommendation for AstraZeneca's Calquence in chronic lymphocytic leukaemia populations https://t.co/N5hbZ20fjN https://t.co/G72Vaz3HQ2"
  },
  "1336340134833180677": {
    "tweet_author": "Cpl Life Sciences",
    "tweet_text": ".@NICEComms backs @AstraZeneca Calquence for chronic lymphocytic #leukaemia https://t.co/5Ex1ktIoN2 #regulatory"
  },
  "1336325313760903174": {
    "tweet_author": "Targeted Oncology",
    "tweet_text": "Dr. Brown discusses the implications of the findings from a pooled analysis of cardiovascular events from studies of the next-generation BTK inhibitor acalabrutinib monotherapy as treatment of patients with chronic lymphocytic leukemia.\nhttps://t.co/43pVoOkpdi #leusm #ASH20"
  },
  "1336321127652605954": {
    "tweet_author": "Pharma News",
    "tweet_text": "Eligible patients in England with Chronic Lymphocytic Leukaemia (CLL) granted immediate access to Calquence\u25bc (acalabrutinib) following positive NICE recommendation\nhttps://t.co/zZJpwgS0in\n#news #pharma #clinicalresearch #biotech #lifesciences #medical #healthcare #pharmiweb https://t.co/UcoVLdYEHl"
  },
  "1336321119490617345": {
    "tweet_author": "Pharma News",
    "tweet_text": "Calquence data across four trials reinforces cardiovascular safety profile in patients with chronic lymphocytic leukaemia\nhttps://t.co/girQo6U81g\n#news #pharma #clinicalresearch #biotech #lifesciences #medical #healthcare #pharmiweb https://t.co/GLZtdpTDa1"
  },
  "1336316195147034624": {
    "tweet_author": "Jon Angelo",
    "tweet_text": "NICE recommendation for AstraZeneca's Calquence in chronic lymphocytic leukaemia populations : https://t.co/bJq1uJ8HW5 #pharmaceutical"
  },
  "1336306905598332930": {
    "tweet_author": "NwokeAgulu",
    "tweet_text": "Pooled Analysis of 4 Clinical Trials Reflects Low Cardiac Risk With Acalabrutinib in\u00a0CLL https://t.co/vpFSnR8Hv9"
  },
  "1336305870800642050": {
    "tweet_author": "Prescient Healthcare Group",
    "tweet_text": "Prescient coverage of #ASH2020, Day 3: Chronic Lymphocytic Leukemia (#CLL) \u2013 #ROR1inhibitor #MDM2inhibitor #ibrutinib #acalabrutinib #zanubritinib #ublituximab #LOXO305 https://t.co/LA8DLPmHMq https://t.co/UKc4Q5EVMI"
  },
  "1336300128064430082": {
    "tweet_author": "OncLive.com",
    "tweet_text": "Pooled Analysis of 4 Clinical Trials Reflects Low Cardiac Risk With Acalabrutinib in CLL @DanaFarber @ASH_hematology #ASH20 #leusm https://t.co/qIUwM0DrlB"
  },
  "1336297360167641088": {
    "tweet_author": "Paperbirds_Hematology",
    "tweet_text": "New clinical trial: Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia https://t.co/5eCCEez64l #CLL #leusm #hematology"
  },
  "1336281796418416642": {
    "tweet_author": "Smart Clinical Pharmacology",
    "tweet_text": "Aprobaci\u00f3n de acalabrutinib contra leucemia linfoc\u00edtica cr\u00f3nica\u00a0en la Uni\u00f3n Europea https://t.co/mmuj7l3Xgj via @medscape"
  },
  "1336254493747507200": {
    "tweet_author": "PHARMABOX.IN",
    "tweet_text": "NICE backs AZ\u2019 Calquence for chronic lymphocytic leukaemia https://t.co/dmm83g8Osj"
  },
  "1336251799028817920": {
    "tweet_author": "PharmaTimes",
    "tweet_text": "NICE backs AZ' Calquence for chronic lymphocytic leukaemia https://t.co/QseroJzMbw #pharmanews #pharma"
  },
  "1336246591573741568": {
    "tweet_author": "1stOncology",
    "tweet_text": "#Astrazeneca reported that #Calquence data across four trials reinforces #Cardiovascular safety profile in patients with #ChronicLymphocyticLeukaemia https://t.co/4HC742Om8M"
  },
  "1336246534740930560": {
    "tweet_author": "1stOncology",
    "tweet_text": "#Astrazeneca reported that #Calquence data across four trials reinforces #cardiovascular safety profile in patients with #ChronicLymphocyticLeukaemia https://t.co/4HC742Om8M"
  },
  "1336173663893266432": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A New CALQUENCE clinical data were released at ASH."
  },
  "1336173663691956227": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A New CALQUENCE clinical data were released at ASH."
  },
  "1336173663423524864": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A New CALQUENCE clinical data were released at ASH."
  },
  "1336173662106423296": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A New CALQUENCE clinical data were released at ASH."
  },
  "1336173660336390145": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A This year\u2019s all-virtual ASH 2020 conference featured clinical data about CALQUENCE\u2014a treatment option for adults with CLL. #ASH20"
  },
  "1336139674578870272": {
    "tweet_author": "vshariharakrishnan",
    "tweet_text": "ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/zwG2Vq7Riu"
  },
  "1336122854279143425": {
    "tweet_author": "Joseph Cioccio, DO",
    "tweet_text": "The only pts to still benefit from chemo in #cll are young with unmutated IGHV and no TP53 or 17pdel otherwise front line tx is chemo free! \n\nPreferred tx either venetoclax+obinatuzumab or acalabrutinib w/ or w/o CD20 moab #ASH2020 https://t.co/zpspQNy8y1"
  },
  "1336062988978151425": {
    "tweet_author": "PHARMABOX.IN",
    "tweet_text": "AstraZeneca Reports Long-Term Efficacy and Tolerability of Calquence (acalabrutinib) in P-ll ACE-LY-004 Study for MCL https://t.co/JODdUoN3UF"
  },
  "1336052359223447552": {
    "tweet_author": "Toby Eyre",
    "tweet_text": "Pleased to be leading UK @NCRI_partners CARAMEL pilot trial in older pts with 1L #acalabrutinib #rituximab in elderly pts unfit for standard immunochemotherapy in #MCL \n\nHopefully opening Q1-2 2021. How will it compare to #ibrutinib-R phase II data? https://t.co/5LMHoxGK6y"
  },
  "1336050170816040964": {
    "tweet_author": "****",
    "tweet_text": "AwesomeCapital: ASH: AstraZeneca's Calquence, BeiGene's Brukinsa t... https://t.co/8Ro1SCDvhe"
  },
  "1336036395903815691": {
    "tweet_author": "Investor News",
    "tweet_text": "CALQUENCE Data Across Four Trials Reinforces Cardiovascular Safety Profile in Patients With Chronic Lymphocytic Leukemia $AZN https://t.co/oGzpJRnaOf"
  },
  "1336031533103198211": {
    "tweet_author": "BrainSights iOS App",
    "tweet_text": "CORRECTING and REPLACING\u00a0CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma - Neuro Central via BrainSights for iOS https://t.co/SZ6IN4MAJt"
  },
  "1336023653239181314": {
    "tweet_author": "Targeted Oncology",
    "tweet_text": "Dr. Brown discusses the implications of the findings from a pooled analysis of cardiovascular events from studies of the next-generation BTK inhibitor acalabrutinib monotherapy as treatment of patients with chronic lymphocytic leukemia.\nhttps://t.co/43pVoOC0BS #ASH20 #leusm"
  },
  "1336005330564747265": {
    "tweet_author": "Pharma Top News",
    "tweet_text": "ASH 2020: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice | FiercePharma #pharmatopnews #oncology #oncologytopnews https://t.co/gBB1X0TTK1"
  },
  "1335992731844296706": {
    "tweet_author": "David Ledger",
    "tweet_text": "Calquence shows long-term efficacy and tolerability in MCL https://t.co/xuH2beSMTw https://t.co/ogGl49uKl6"
  },
  "1335992597005873154": {
    "tweet_author": "SeattleCancerCareAlliance",
    "tweet_text": "Today at #ASH20: Poster session with @MShadman, MD, MPH - \"2947 Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib\" https://t.co/d0HTtQeUKo #Hematology https://t.co/gzja1GKcQZ"
  },
  "1335991432436322310": {
    "tweet_author": "IMPharma News",
    "tweet_text": "CALQUENCE Data Across Four Trials Reinforces Cardiovascular Safety Profile in Patients With Chronic Lymphocytic Leukemia \nhttps://t.co/oF55LNXw5K"
  },
  "1335981212104445953": {
    "tweet_author": "Biotech & Tech Stock Focus",
    "tweet_text": "$AZN CALQUENCE Data Across Four Trials Reinforces Cardiovascular Safety Profile in Patients With Chronic Lymphocytic Leukemia  | Business Wire https://t.co/liPcF2DFs7"
  },
  "1335980641062592517": {
    "tweet_author": "Crwe World",
    "tweet_text": "CORRECTING and REPLACING&amp;nbsp;CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With R https://t.co/cJ8P1WttRC"
  },
  "1335977403903045641": {
    "tweet_author": "Company News HQ",
    "tweet_text": "Calquence data across four trials reinforces cardiovascular safety profile in patients with chronic lymphocytic https://t.co/1NVeuD39Ja"
  },
  "1335976287664545796": {
    "tweet_author": "Anne Sweden",
    "tweet_text": "Consider @CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL). It\u2019s a convenient oral 2x a day capsule. Learn more: #bloodcancerawareness https://t.co/3UMq906vmi #ad https://t.co/kpqsMVmGLQ"
  },
  "1335975588473884674": {
    "tweet_author": "LifeProNow-Pharma-Research and News",
    "tweet_text": "AZ\u2019s Calquence shows long-term efficacy and tolerability in MCL\nhttps://t.co/HAuiZ3uWDS https://t.co/XaryjEn1k0"
  },
  "1335972953180221443": {
    "tweet_author": "Pharmacutical Daily",
    "tweet_text": "CORRECTING and REPLACING\u00a0CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell\u00a0Lymphoma https://t.co/TLyHApsVh2"
  },
  "1335972786842578944": {
    "tweet_author": "The British Journal of Cardiology",
    "tweet_text": "Pooled analysis @ASH_hematology of cardiovascular safety data in 762 patients treated with Calquence (acalabrutinib) monotherapy for chronic lymphocytic leukaemia (CLL), the most common adult leukaemia, showed a low incidence of cardiac adverse events. @AstraZeneca @BCOSCardioOnc"
  },
  "1335969803404775429": {
    "tweet_author": "Devdiscourse",
    "tweet_text": "BRIEF-AstraZeneca Says Less Than 1% Of Patients Treated With Calquence Discontinued Treatment Due To Cardiac Adverse Events In Pooled Analysis https://t.co/gF1PgElQWf"
  },
  "1335967327200874496": {
    "tweet_author": "OTC Dynamics, Inc.",
    "tweet_text": "$AZN CORRECTING and REPLACING\u00a0CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma https://t.co/9bOBPbYxpl"
  },
  "1335967035210153989": {
    "tweet_author": "Stock Titan",
    "tweet_text": "$AZN CORRECTING and REPLACING\u00a0CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma\nhttps://t.co/bDMcZaWJHo"
  },
  "1335966935134195717": {
    "tweet_author": "Investor News",
    "tweet_text": "CORRECTING and REPLACING CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle .. $AZN https://t.co/MdCwShoaPB"
  },
  "1335966873796685824": {
    "tweet_author": "Keeping Life Sane",
    "tweet_text": "Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It\u2019s a prescription oral 2x a day capsule. Learn more: https://t.co/HoUcLnvD1x #bloodcancerawareness #ad https://t.co/ozEJghGHae https://t.co/2Mgh0iUKcD"
  },
  "1335965217101111296": {
    "tweet_author": "OTC Dynamics, Inc.",
    "tweet_text": "$AZN CALQUENCE Data Across Four Trials Reinforces Cardiovascular Safety Profile in Patients With Chronic Lymphocytic Leukemia https://t.co/CI7lKInfd7"
  },
  "1335964129224495104": {
    "tweet_author": "Shifting Wealth",
    "tweet_text": "AstraZeneca says data from four Calquence trials reinforces CV safety in CLL\n$AZN"
  },
  "1335964040816836610": {
    "tweet_author": "Cision News",
    "tweet_text": "Calquence data across four trials reinforces cardiovascular safety profile in patients with chronic lymphocytic leukaemia https://t.co/fpte97uDSd"
  },
  "1335963626889416704": {
    "tweet_author": "AstraZenecaUS",
    "tweet_text": "Cardiovascular (CV) adverse events may be a key consideration in chronic lymphocytic #leukemia (CLL) treatment decisions. Today at #ASH20 we\u2019re presenting results of an analysis of pooled CV safety data across four trials in CLL. Learn more: https://t.co/4Gi0xwEVVo https://t.co/JyV0NGFlmC"
  },
  "1335963556852875264": {
    "tweet_author": "Stock Titan",
    "tweet_text": "$AZN CALQUENCE Data Across Four Trials Reinforces Cardiovascular Safety Profile in Patients With Chronic Lymphocytic Leukemia\nhttps://t.co/s7AmAnUU6Z"
  },
  "1335958846553001986": {
    "tweet_author": "Biotech & Tech Stock Focus",
    "tweet_text": "$AZN $BGNE ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/0jrHkdtOnR"
  },
  "1335957750744903680": {
    "tweet_author": "Dr. Carsten Wenzel",
    "tweet_text": "Calquence shows long-term efficacy and tolerability in MCL https://t.co/JvHjWIyvfe https://t.co/ksGNByhnKb"
  },
  "1335940206223106048": {
    "tweet_author": "BiopharmaAsia",
    "tweet_text": "ACE-LY-004 Phase II trial results substantiate established efficacy and safety profile of Calquence - https://t.co/b8JIeZLF4S"
  },
  "1335933768528490496": {
    "tweet_author": "Prescient Healthcare Group",
    "tweet_text": "Prescient coverage of #ASH2020, Day 2: Chronic Lymphocytic Leukemia (#CLL) \u2013 #acalabrutinib #venetoclax #obinutuzumab https://t.co/MRBDl9AdeQ https://t.co/WLy1gaofTm"
  },
  "1335917885143863298": {
    "tweet_author": "CHItraders",
    "tweet_text": "$AZN AstraZeneca's Calquence shows long-term efficacy and tolerability in patients with blood cancer https://t.co/zBfxEhQ1au"
  },
  "1335914582188187648": {
    "tweet_author": "WIC\u049a\u01b8\ufe0e\u0110\u2727\u0218P\u013fI\u04ac\u015a",
    "tweet_text": "\u25b6\ufe0e AstraZeneca's Calquence shows long-term efficacy and tolerability in patients with blood cancer https://t.co/FOL47mRFbO VI\u039b WIC\u049a\u01b8\ufe0e\u0110\u2727\u0218P\u013fI\u04ac\u015a FIN\u039bNCI\u039bL RE\u039bDS"
  },
  "1335913278371926018": {
    "tweet_author": "Gordon Gekko",
    "tweet_text": "AstraZeneca's Calquence shows long-term efficacy and tolerability in patients with blood cancer https://t.co/a7IfrxMoGZ"
  },
  "1335913076416270336": {
    "tweet_author": "Investor News",
    "tweet_text": "AstraZeneca's Calquence shows long-term efficacy and tolerability in patients with blood cancer $AZN https://t.co/8yWmcnr1VS"
  },
  "1335912165979561991": {
    "tweet_author": "Breaking News",
    "tweet_text": "$AZN - AstraZeneca's Calquence shows long-term efficacy and tolerability in patients with blood cancer https://t.co/IbDBcH5OeL"
  },
  "1335904449622061056": {
    "tweet_author": "PharmaTimes",
    "tweet_text": "Calquence shows long-term efficacy and tolerability in MCL https://t.co/4f3L0E9SVK #pharmanews #pharma"
  },
  "1335901590432215043": {
    "tweet_author": "PHARMABOX.IN",
    "tweet_text": "Calquence shows long-term efficacy and tolerability in MCL https://t.co/4DdzNkc7tO"
  },
  "1335894459070828544": {
    "tweet_author": "PharmaShots - Incisive news in 3 shots",
    "tweet_text": "AstraZeneca Reports Long-Term Efficacy and Tolerability of Calquence (acalabrutinib) in P-ll ACE-LY-004 Study for MCL @Pharmashot @AstraZeneca \nhttps://t.co/SSI6xZmusR https://t.co/y57kfUqk3D"
  },
  "1335885262078025728": {
    "tweet_author": "Medicircle.in",
    "tweet_text": "Long-term follow-up results from the positive ACE-LY-004 Phase II trial showed patients with relapsed or refractory mantle cell lymphoma (MCL) treated with Calquence (acalabrutinib) remained\n #LatestPharmaNewsDec7 #LatestAstrazenecaNewsDec7 \nhttps://t.co/GQHZzUJ6BW"
  },
  "1335866653892960261": {
    "tweet_author": "1stOncology",
    "tweet_text": "#Astrazeneca reported that #Calquence shows long-term efficacy and tolerability at three years  for patients with #relapsed or #refractory #mantlecelllymphoma $AZN https://t.co/iJGSKQcdkZ"
  },
  "1335811398467612672": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20"
  },
  "1335811276476387329": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20"
  },
  "1335811275561918464": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20"
  },
  "1335811274802929664": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20"
  },
  "1335811274429620224": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20"
  },
  "1335811274177794048": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20"
  },
  "1335811273045528576": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20"
  },
  "1335811272881758208": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20"
  },
  "1335811272479223808": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20"
  },
  "1335811272475111425": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20"
  },
  "1335811272453935106": {
    "tweet_author": "CALQUENCE\u00ae (acalabrutinib)",
    "tweet_text": "https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20"
  },
  "1335744469673525249": {
    "tweet_author": "cafepharma",
    "tweet_text": "ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/2Dd7CdJ1D8"
  },
  "1335718758451646467": {
    "tweet_author": "Shifting Wealth",
    "tweet_text": "CALQUENCE shows long-term efficacy, tolerability at 3 years in R/R MCL \n$AZN"
  },
  "1335718044153257984": {
    "tweet_author": "analyst land news",
    "tweet_text": "ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/0NqwPRmrmn https://t.co/1fsa0r89Co"
  },
  "1335705645006327815": {
    "tweet_author": "Enosi Life Sciences",
    "tweet_text": "These \u201ccytokine storms\" are created when there are high levels of pro-inflammatory TNF.\n\n\"...some COVID-19 patients suffer from \"cytokine storms,\" in which immune systems end up attacking the body after getting revving up to fight off the coronavirus. \" https://t.co/TSbSVAaRX6"
  },
  "1335701979318935552": {
    "tweet_author": "ExBulletin",
    "tweet_text": "ASH: AstraZeneca\u2019s Calquence and BeiGene\u2019s Brukinsa are turning heads with new data, putting Imbruvica on high\u00a0alert https://t.co/MP6bBWr9E2"
  },
  "1335700302406664192": {
    "tweet_author": "Dr Timos Papagatsias",
    "tweet_text": "ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/nb6TYqWit2 #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #productmarketing #healthcare #biotech https://t.co/5Cn35fMGtb"
  },
  "1335698575792148481": {
    "tweet_author": "Wall St. Justin Bieber think.trade\ud83d\udcad",
    "tweet_text": "\ud83d\udcf0 NEWS ALERT: AstraZeneca Announced Calquence Shows Long-term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma in Presentation at ASH 2020\n\ud83d\udd70 Time/Date: 2020-12-06T21:31:24.535000+00:00\n-think.trade"
  },
  "1335692498002354178": {
    "tweet_author": "PharmaCrowd",
    "tweet_text": "ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/02Gy4NpuLI https://t.co/Yz6EF7oAh2"
  },
  "1335692400354877440": {
    "tweet_author": "FintechZoom",
    "tweet_text": "New article: \"Johnson &amp; Johnson - ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice\" has been published on Fintech Zoom - https://t.co/adPNJ6RbBF @FintechZoom #Fintech #Blockchain #Crypto #Cryptocurrency #ICO"
  },
  "1335688725980979204": {
    "tweet_author": "Continental Clinical",
    "tweet_text": "ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/S54IU6veT0"
  },
  "1335681794402881537": {
    "tweet_author": "NewExpressNews",
    "tweet_text": "ASH: AstraZeneca\u2019s Calquence, BeiGene\u2019s Brukinsa turn heads with new data, putting Imbruvica on\u00a0notice https://t.co/w4Z9ZSGPPo"
  },
  "1335679918525526018": {
    "tweet_author": "PHARMABOX.IN",
    "tweet_text": "ASH: AstraZeneca\u2019s Calquence, BeiGene\u2019s Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/xgInJQBg6s"
  },
  "1335679662958071809": {
    "tweet_author": "\u524d\u7530\u9759\u543e\uff5c\u6d77\u5916\u60c5\u5831\u6d3b\u7528\u30b3\u30f3\u30b5\u30eb\u30bf\u30f3\u30c8\u3000Insights4 Pharma\u7de8\u96c6\u9577",
    "tweet_text": "ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/5oYzzhKiLA"
  },
  "1335674215983407104": {
    "tweet_author": "Company News HQ",
    "tweet_text": "Calquence shows long-term efficacy and tolerability at three years for patients with relapsed or refractory mantle https://t.co/GQ0bdnvfBD"
  },
  "1335669146030313473": {
    "tweet_author": "BrainSights iOS App",
    "tweet_text": "CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma - Neuro Central via BrainSights for iOS https://t.co/ni7XTtquFd"
  },
  "1335657756842467329": {
    "tweet_author": "Anthony Mato",
    "tweet_text": "Very thoughtful answer. Thanks for taking my question. Clive Zent discussing which may be best the anti CD antibody to pair with the BTK inhibitor acalabrutinib. https://t.co/dnhMDywRce"
  },
  "1335628087342600193": {
    "tweet_author": "Pharmacutical Daily",
    "tweet_text": "CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell\u00a0Lymphoma https://t.co/lyPJvlt8Pj"
  },
  "1335615746278232068": {
    "tweet_author": "Stock Market News",
    "tweet_text": "CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma https://t.co/ejOAcuqoXi #StockMarket"
  },
  "1335606574849482754": {
    "tweet_author": "Hottest Stocks Now",
    "tweet_text": "$AZN Reveals findings from mid-stage trial evaluating CALQUENCE in patients with relapsed or refractory mantle cell lymphoma      #Astrazeneca       #MCL       #mantlecelllymphoma     #lymphoma      https://t.co/mNw8szIDyN"
  },
  "1335606445920972800": {
    "tweet_author": "OTC Dynamics, Inc.",
    "tweet_text": "$AZN CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma https://t.co/py9vCpQGfd"
  },
  "1335604254136913921": {
    "tweet_author": "Corporate News",
    "tweet_text": "$AZN CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma https://t.co/LNACBNGPHa"
  },
  "1335603847465603074": {
    "tweet_author": "IMPharma News",
    "tweet_text": "CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma \nhttps://t.co/RfVqm1ITyJ"
  },
  "1335602524351508481": {
    "tweet_author": "Investor News",
    "tweet_text": "CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma $AZN https://t.co/eRVMJfkQlL"
  },
  "1335601900037709831": {
    "tweet_author": "Crwe World",
    "tweet_text": "CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle C https://t.co/y3FjZiBpqG"
  },
  "1335601278748004352": {
    "tweet_author": "Latest News from Business Wire",
    "tweet_text": "CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma https://t.co/Vf692VoBYt https://t.co/Th59UhyUxL"
  },
  "1335600906985992193": {
    "tweet_author": "AstraZenecaUS",
    "tweet_text": "Today we announced long-term follow-up results of the ACE-LY-004 trial in relapsed or refractory mantle cell #lymphoma (MCL) at #ASH20. Learn more about this latest development for people living with MCL: https://t.co/elpwOKu66y https://t.co/QJrSITwFNa"
  }
}
